US20030165458A1 - Diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism - Google Patents
Diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism Download PDFInfo
- Publication number
- US20030165458A1 US20030165458A1 US10/327,631 US32763102A US2003165458A1 US 20030165458 A1 US20030165458 A1 US 20030165458A1 US 32763102 A US32763102 A US 32763102A US 2003165458 A1 US2003165458 A1 US 2003165458A1
- Authority
- US
- United States
- Prior art keywords
- disease
- complement
- pathway
- functional equivalents
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000037356 lipid metabolism Effects 0.000 title claims abstract description 43
- 238000011282 treatment Methods 0.000 title claims abstract description 32
- 230000036737 immune function Effects 0.000 title description 8
- 230000002265 prevention Effects 0.000 title description 7
- 238000003745 diagnosis Methods 0.000 title description 4
- 230000037361 pathway Effects 0.000 claims abstract description 136
- 230000000295 complement effect Effects 0.000 claims abstract description 96
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 72
- 150000002632 lipids Chemical class 0.000 claims abstract description 71
- 201000010099 disease Diseases 0.000 claims abstract description 62
- 239000002245 particle Substances 0.000 claims abstract description 43
- 230000001404 mediated effect Effects 0.000 claims abstract description 32
- 230000001613 neoplastic effect Effects 0.000 claims abstract description 19
- 210000000987 immune system Anatomy 0.000 claims abstract description 17
- 208000015181 infectious disease Diseases 0.000 claims abstract description 16
- 208000014951 hematologic disease Diseases 0.000 claims abstract description 11
- 208000018706 hematopoietic system disease Diseases 0.000 claims abstract description 10
- 230000002458 infectious effect Effects 0.000 claims abstract description 9
- 230000001363 autoimmune Effects 0.000 claims abstract description 8
- 230000007547 defect Effects 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 57
- 230000024203 complement activation Effects 0.000 claims description 54
- 230000000694 effects Effects 0.000 claims description 38
- 210000003743 erythrocyte Anatomy 0.000 claims description 36
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 35
- 208000026278 immune system disease Diseases 0.000 claims description 29
- 102000004856 Lectins Human genes 0.000 claims description 27
- 108090001090 Lectins Proteins 0.000 claims description 27
- 239000002523 lectin Substances 0.000 claims description 27
- 108010027006 Apolipoproteins B Proteins 0.000 claims description 26
- 102000018616 Apolipoproteins B Human genes 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 24
- 210000002966 serum Anatomy 0.000 claims description 22
- 230000001419 dependent effect Effects 0.000 claims description 21
- 102000003780 Clusterin Human genes 0.000 claims description 19
- 108090000197 Clusterin Proteins 0.000 claims description 19
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 16
- 108010031318 Vitronectin Proteins 0.000 claims description 16
- 102100035140 Vitronectin Human genes 0.000 claims description 16
- 238000011321 prophylaxis Methods 0.000 claims description 15
- 230000001771 impaired effect Effects 0.000 claims description 14
- 102400000630 Acylation stimulating protein Human genes 0.000 claims description 13
- 101800000415 Acylation stimulating protein Proteins 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 102000014150 Interferons Human genes 0.000 claims description 12
- 108010050904 Interferons Proteins 0.000 claims description 12
- 102000015696 Interleukins Human genes 0.000 claims description 12
- 108010063738 Interleukins Proteins 0.000 claims description 12
- 102000006495 integrins Human genes 0.000 claims description 12
- 108010044426 integrins Proteins 0.000 claims description 12
- 229940047124 interferons Drugs 0.000 claims description 12
- 229940047122 interleukins Drugs 0.000 claims description 12
- 102000016289 Cell Adhesion Molecules Human genes 0.000 claims description 11
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims description 11
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 10
- 208000023275 Autoimmune disease Diseases 0.000 claims description 10
- 102000003712 Complement factor B Human genes 0.000 claims description 10
- 108090000056 Complement factor B Proteins 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 239000003921 oil Substances 0.000 claims description 9
- 235000019198 oils Nutrition 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- 208000035473 Communicable disease Diseases 0.000 claims description 8
- 230000000923 atherogenic effect Effects 0.000 claims description 8
- 108010006303 Carboxypeptidases Proteins 0.000 claims description 7
- 102000005367 Carboxypeptidases Human genes 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- 238000001727 in vivo Methods 0.000 claims description 6
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 5
- 102000000589 Interleukin-1 Human genes 0.000 claims description 5
- 108010002352 Interleukin-1 Proteins 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 5
- 239000002480 mineral oil Substances 0.000 claims description 5
- 235000010446 mineral oil Nutrition 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 229960003433 thalidomide Drugs 0.000 claims description 5
- 108090000371 Esterases Proteins 0.000 claims description 4
- 101150106931 IFNG gene Proteins 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 230000002503 metabolic effect Effects 0.000 claims description 4
- 235000016709 nutrition Nutrition 0.000 claims description 4
- 239000004006 olive oil Substances 0.000 claims description 4
- 235000008390 olive oil Nutrition 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 238000000684 flow cytometry Methods 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 230000003053 immunization Effects 0.000 claims description 3
- 238000002649 immunization Methods 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 230000005875 antibody response Effects 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 230000009257 reactivity Effects 0.000 claims description 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims 14
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims 4
- 238000001514 detection method Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004154 complement system Effects 0.000 abstract description 26
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 16
- 241000282414 Homo sapiens Species 0.000 abstract description 16
- 102000004895 Lipoproteins Human genes 0.000 abstract description 11
- 108090001030 Lipoproteins Proteins 0.000 abstract description 11
- 230000001105 regulatory effect Effects 0.000 abstract description 8
- 230000008030 elimination Effects 0.000 abstract description 6
- 238000003379 elimination reaction Methods 0.000 abstract description 6
- 210000002751 lymph Anatomy 0.000 abstract description 3
- 230000000845 anti-microbial effect Effects 0.000 abstract description 2
- 230000007123 defense Effects 0.000 abstract description 2
- 230000002068 genetic effect Effects 0.000 abstract description 2
- 210000004698 lymphocyte Anatomy 0.000 abstract description 2
- 230000000813 microbial effect Effects 0.000 abstract description 2
- 238000002255 vaccination Methods 0.000 abstract description 2
- 230000017531 blood circulation Effects 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 108010004103 Chylomicrons Proteins 0.000 description 54
- 108010087870 Mannose-Binding Lectin Proteins 0.000 description 52
- 102000009112 Mannose-Binding Lectin Human genes 0.000 description 52
- 210000004369 blood Anatomy 0.000 description 32
- 239000008280 blood Substances 0.000 description 32
- 239000000306 component Substances 0.000 description 32
- 108010004942 Chylomicron Remnants Proteins 0.000 description 29
- 102100022133 Complement C3 Human genes 0.000 description 29
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 27
- 101000901154 Homo sapiens Complement C3 Proteins 0.000 description 26
- 210000002381 plasma Anatomy 0.000 description 25
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 21
- 210000004185 liver Anatomy 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 18
- 230000007812 deficiency Effects 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 230000004913 activation Effects 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 15
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 230000000291 postprandial effect Effects 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 14
- 102100033772 Complement C4-A Human genes 0.000 description 13
- 101000710884 Homo sapiens Complement C4-A Proteins 0.000 description 13
- 108010007622 LDL Lipoproteins Proteins 0.000 description 13
- 102000007330 LDL Lipoproteins Human genes 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 108010001831 LDL receptors Proteins 0.000 description 10
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 10
- 102000043296 Lipoprotein lipases Human genes 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 9
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 9
- 239000012190 activator Substances 0.000 description 9
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 235000021588 free fatty acids Nutrition 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 210000004379 membrane Anatomy 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 150000003626 triacylglycerols Chemical class 0.000 description 9
- 239000011719 vitamin A Substances 0.000 description 9
- 235000019155 vitamin A Nutrition 0.000 description 9
- 229940045997 vitamin a Drugs 0.000 description 9
- 101150102415 Apob gene Proteins 0.000 description 8
- 108010025628 Apolipoproteins E Proteins 0.000 description 8
- 102000013918 Apolipoproteins E Human genes 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 108010078015 Complement C3b Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 108010046315 IDL Lipoproteins Proteins 0.000 description 7
- 108700022034 Opsonin Proteins Proteins 0.000 description 7
- 108010047295 complement receptors Proteins 0.000 description 7
- 102000006834 complement receptors Human genes 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 210000001789 adipocyte Anatomy 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 230000003111 delayed effect Effects 0.000 description 6
- 230000013595 glycosylation Effects 0.000 description 6
- 238000006206 glycosylation reaction Methods 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000002101 lytic effect Effects 0.000 description 6
- 210000001539 phagocyte Anatomy 0.000 description 6
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 5
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 5
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 5
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 5
- 239000013256 coordination polymer Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 5
- 229950006780 n-acetylglucosamine Drugs 0.000 description 5
- 235000002378 plant sterols Nutrition 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 5
- 101710095342 Apolipoprotein B Proteins 0.000 description 4
- 102000007592 Apolipoproteins Human genes 0.000 description 4
- 108010071619 Apolipoproteins Proteins 0.000 description 4
- 108010053085 Complement Factor H Proteins 0.000 description 4
- 102000016550 Complement Factor H Human genes 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 4
- 102100039373 Membrane cofactor protein Human genes 0.000 description 4
- 241000288906 Primates Species 0.000 description 4
- 101710172711 Structural protein Proteins 0.000 description 4
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000008588 hemolysis Effects 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 244000000010 microbial pathogen Species 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 229940068065 phytosterols Drugs 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 3
- 101800001976 Apolipoprotein B-48 Proteins 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 108010028780 Complement C3 Proteins 0.000 description 3
- 201000001376 Familial Combined Hyperlipidemia Diseases 0.000 description 3
- 229920001503 Glucan Polymers 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 101000710883 Homo sapiens Complement C4-B Proteins 0.000 description 3
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 3
- 102000004528 Mannose-Binding Protein-Associated Serine Proteases Human genes 0.000 description 3
- 108010042484 Mannose-Binding Protein-Associated Serine Proteases Proteins 0.000 description 3
- 102100027637 Plasma protease C1 inhibitor Human genes 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- 239000004074 complement inhibitor Substances 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- -1 dextran sulphates Chemical class 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 210000000497 foam cell Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 230000007124 immune defense Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 238000005199 ultracentrifugation Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- 108010089414 Anaphylatoxins Proteins 0.000 description 2
- 102400000352 Apolipoprotein B-48 Human genes 0.000 description 2
- 108010060219 Apolipoprotein E2 Proteins 0.000 description 2
- 102000006410 Apoproteins Human genes 0.000 description 2
- 108010083590 Apoproteins Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102100022002 CD59 glycoprotein Human genes 0.000 description 2
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 2
- 102000004405 Collectins Human genes 0.000 description 2
- 108090000909 Collectins Proteins 0.000 description 2
- 108010028774 Complement C1 Proteins 0.000 description 2
- 102100025406 Complement C1s subcomponent Human genes 0.000 description 2
- 102000000989 Complement System Proteins Human genes 0.000 description 2
- 108010069112 Complement System Proteins Proteins 0.000 description 2
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 2
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 2
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 2
- 201000010252 Hyperlipoproteinemia Type III Diseases 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 102000001851 Low Density Lipoprotein Receptor-Related Protein-1 Human genes 0.000 description 2
- 108010015340 Low Density Lipoprotein Receptor-Related Protein-1 Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 206010060751 Type III hyperlipidaemia Diseases 0.000 description 2
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229940076810 beta sitosterol Drugs 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 2
- 235000000431 campesterol Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 108010069938 complement C5b-7 complex Proteins 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 239000006225 natural substrate Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000004848 nephelometry Methods 0.000 description 2
- 230000003448 neutrophilic effect Effects 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 2
- 235000016831 stigmasterol Nutrition 0.000 description 2
- 229940032091 stigmasterol Drugs 0.000 description 2
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 108010003529 Alternative Pathway Complement C3 Convertase Proteins 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- 108010008150 Apolipoprotein B-100 Proteins 0.000 description 1
- 108010060215 Apolipoprotein E3 Proteins 0.000 description 1
- 102000008128 Apolipoprotein E3 Human genes 0.000 description 1
- 108010060159 Apolipoprotein E4 Proteins 0.000 description 1
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 108010009575 CD55 Antigens Proteins 0.000 description 1
- 108010055167 CD59 Antigens Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102100026678 Carboxypeptidase N catalytic chain Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 102000015612 Complement 3b Receptors Human genes 0.000 description 1
- 108010024114 Complement 3b Receptors Proteins 0.000 description 1
- 108090000044 Complement Factor I Proteins 0.000 description 1
- 102000003706 Complement factor D Human genes 0.000 description 1
- 108090000059 Complement factor D Proteins 0.000 description 1
- 102100035431 Complement factor I Human genes 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 101150005874 DEF1 gene Proteins 0.000 description 1
- 208000034599 Dysbetalipoproteinemia Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 206010053240 Glycogen storage disease type VI Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 206010056438 Growth hormone deficiency Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
- 101000910843 Homo sapiens Carboxypeptidase N catalytic chain Proteins 0.000 description 1
- 101001081555 Homo sapiens Plasma protease C1 inhibitor Proteins 0.000 description 1
- 208000037171 Hypercorticoidism Diseases 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
- 101710172064 Low-density lipoprotein receptor-related protein Proteins 0.000 description 1
- 101710146216 Membrane cofactor protein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 108010046016 Peanut Agglutinin Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 108010005642 Properdin Proteins 0.000 description 1
- 102100038567 Properdin Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102000000528 Pulmonary Surfactant-Associated Proteins Human genes 0.000 description 1
- 108010041520 Pulmonary Surfactant-Associated Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 108010023795 VLDL receptor Proteins 0.000 description 1
- 102100039066 Very low-density lipoprotein receptor Human genes 0.000 description 1
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000005255 adrenal gland hyperfunction Diseases 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 108010006523 asialoglycoprotein receptor Proteins 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000007816 calorimetric assay Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 108010018927 conglutinin Proteins 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012084 conversion product Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 101150060629 def gene Proteins 0.000 description 1
- 101150060894 def2 gene Proteins 0.000 description 1
- 238000002298 density-gradient ultracentrifugation Methods 0.000 description 1
- QCUFYOBGGZSFHY-UHFFFAOYSA-N depsidomycin Chemical compound O=C1C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(NC=O)C(C)CC)C(C)OC(=O)C2CCCNN2C(=O)C(CC(C)C)NC(=O)C2CCCNN21 QCUFYOBGGZSFHY-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- FRKBLBQTSTUKOV-UHFFFAOYSA-N diphosphatidyl glycerol Natural products OP(O)(=O)OCC(OP(O)(O)=O)COP(O)(O)=O FRKBLBQTSTUKOV-UHFFFAOYSA-N 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- 235000020977 fat-enriched diet Nutrition 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 108010015750 fucose-binding lectin Proteins 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 208000020887 hyperlipoproteinemia type 3 Diseases 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229940028435 intralipid Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 108010077695 lipolysis-stimulated receptor Proteins 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000020925 non fasting Nutrition 0.000 description 1
- 230000000444 normolipidemic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- 230000028503 regulation of lipid metabolic process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 108020002447 serine esterase Proteins 0.000 description 1
- 102000005428 serine esterase Human genes 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 210000001321 subclavian vein Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- YCUVUDODLRLVIC-VPHDGDOJSA-N sudan black b Chemical compound C1=CC(=C23)NC(C)(C)NC2=CC=CC3=C1\N=N\C(C1=CC=CC=C11)=CC=C1\N=N\C1=CC=CC=C1 YCUVUDODLRLVIC-VPHDGDOJSA-N 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000002978 thoracic duct Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
Definitions
- the invention relates to the diagnosis, prevention, and/or treatment of immunological diseases that are induced by disturbances in lipid metabolism.
- MBL mannose-binding lectin
- Madsen et al. [12] suggested that unexpected non-infective mechanisms are equally likely to play a role in the development of atherosclerosis as are the possibilities of a relationship with infectious microorganisms.
- the role of MBL in the immune system and the use of recombinant MBL in treating deficiencies in the immune system is known in the art (e.g., WO 0070043).
- the present invention teaches how lipid metabolism, complement activation, atherogenic processes and immune responses are physiologically related.
- the present inventors have elucidated a mechanism based on the relationship between lipid metabolism, immune adherence and immunological disorders.
- a novel approach for the diagnosis, prevention, amelioration and/or therapy of immunological disorders that are induced by lipid metabolism and underlying and/or related diseases is presented, which comprises a method for the treatment and/or prophylaxis of immune diseases involving complement activation elements associated with disturbances in the complement/lipid pathway by modulating the activity of one or more elements in said pathway.
- a disease of the immune system and/or an infectious, autoimmune, neoplastic and/or hematological disease interconnected with complement-mediated lipid metabolism and/or an underlying and/or related disease may effectively be treated and/or its severity may be reduced.
- This new method may be implemented in a large range of conditions and in combination with current strategies to lower the occurrence and/or severity of immunological disorders, such as autoimmune disease and neoplastic disease.
- the present invention makes use of the surprising notion that the primary and most ancient function of the complement system is the transport and targeting of lipoproteins (i.e., chylomicrons, VLDL's, LDL's, and their remnants) to the liver, rather than its antimicrobial activity. Based on this new insight, novel preventive measures and treatment modulators of immune diseases involving complement activation pathway elements are introduced.
- lipoproteins i.e., chylomicrons, VLDL's, LDL's, and their remnants
- the invention predicts that low serum levels of the intercellular matrix proteins vitronectin and/or clusterin, which function as regulators of the ‘terminal’ or ‘lytic’ pathways of complement, leads to decreased intravascular integrity of chylomicron remnants. Such a decreased integrity is typically atherogenic and can result in concomitant disease of a more immunological nature.
- the invention relates to the use of purified or enriched physiologic complement components, physiologic complement regulators and/or extrinsic complement modulators of natural (e.g. plant-derived), synthetic, or semi-synthetic origin in the prevention and/or treatment of atherosclerosis and underlying and/or related diseases by substituting for and/or at least diminishing deficiencies in the complement activation pathways.
- the invention provides novel diagnostic tools and formulations of specific and highly effective primary and secondary prevention strategies for disturbances of immune functions influenced by the complement/lipid pathway.
- the present invention provides new and improved methods of prevention, amelioration and/or treatment of disturbed immune functions which are interconnected with lipid metabolism and/or underlying or related diseases.
- the invention further provides new and improved methods of determining the occurrence (diagnosis) of disturbed immune functions interconnected with lipid metabolism and related diseases and teaches how to classify these diseases accordingly.
- the present invention provides for the coordinated design and discovery of new drugs, useful for the treatment of disturbed immune functions interconnected with lipid metabolism and related diseases.
- the present invention provides compositions comprising modulators of the complement activation pathways which can serve as a basis, or an ingredient of a pharmaceutical composition or a food product. Therefore, the present invention also relates to pharmaceutical products or food products that comprise such modulating compositions.
- the present invention provides the use of at least one complement factor or modulator for the manufacture of a medicament for the treatment, amelioration and/or prevention of disturbed immune functions interconnected with lipid metabolism or an underlying and/or related disease. Typically, such treatments would be combined with existing treatments of immune diseases.
- the invention may either inhibit the complement activation pathway or enhance it, depending on the disease to be treated, by modulating the lipid component of the pathway.
- FIG. 1 shows the complement system in schematic representation.
- FIG. 2 shows the two most ancient pathways of the complement system in a schematic representation.
- FIG. 3 shows the relationship between triglyceride rich particles (TRP), their remnants (TRP-R), the position of lipoprotein lipase (LPL), free fatty-acids (FFA), acylation-stimulating protein (ASP), several complement components (C3, factor B and factor D) in relation to triglyceride (TG) uptake by adipocytes and liver-derived very low density lipoproteins (VLDL).
- TRP triglyceride rich particles
- TRP-R remnants
- LPL lipoprotein lipase
- FFA free fatty-acids
- ASP acylation-stimulating protein
- C3, factor B and factor D several complement components in relation to triglyceride (TG) uptake by adipocytes and liver-derived very low density lipoproteins (VLDL).
- FIGS. 4A through E show the binding to chylomicrons of C3, MBL, clusterin and vitronectin as described in example 1.
- FIGS. 5A and B show the effect of immune adherence of triglyceride-rich particles to erythrocytes in blood after staining with Sudan Black as described in example 2.
- FIG. 6 shows the flow cytogram obtained after staining apo B on human erythrocytes as described in example 3.
- FIG. 7 shows the internalization of triglyceride-rich particles in a blood leukocyte as described in example 4.
- FIG. 8 shows the complement/lipid pathway in schematic representation.
- FIG. 9 shows the potency of different substances in the activation of complement in vitro.
- FIG. 10 shows the effects of glycosylated plantstanols on fasting triglycerides, plasma apoB and plasma cholesterol levels over a four month period in a patient with heterozygous Familial Hypercholesterolemia.
- FIG. 11A shows the effect of vitamin A on postprandial C3 plasma concentration after 2 h in healthy lean volunteers.
- FIG. 11B shows the effect of vitamin A on postprandial plasma triglycerid concentration after 2 h in healthy lean volunteers.
- the complement system is a complex signaling system comprising enzymes present in the blood.
- the complement system is involved in the early recognition and clearance from the circulation and tissues of foreign bodies and antigen-antibody complexes (also called immune complexes).
- Complement is recognized as an important, humoral defense system involved in the innate (nonspecific) recognition and elimination from the body of microbial invaders, other foreign particles or molecules, and antigen-antibody complexes.
- C3 convertases Upon the recognition of foreign material in the tissue or blood, the most crucial and abundant complement component, C3, is activated by C3 convertases. This activation triggers a cascade of events that ultimately leads to the clearance of the foreign material.
- C3a represents the N-terminus (77 amino acids) of the ⁇ chain and C3b represents the C-termini of the ⁇ and ⁇ chains.
- C3 convertases, of which various forms exist, can be generated through three different complement activation pathways (FIG. 1) and its synthesis is well regulated.
- the C3-convertase-generating pathways include, in order of descending evolutionary age, the so-called ‘lectin’ pathway (LP), the ‘alternative’ pathway (AP) which is also known as the ‘amplification loop’, and the relatively young ‘classical’ pathway (CP).
- LP so-called ‘lectin’ pathway
- AP alternative’ pathway
- CP relatively young ‘classical’ pathway
- an additional system known as the ‘terminal’ or ‘lytic’ pathway has developed on top of the complement activation system, which can destabilize membranes of e.g. Gram-negative bacteria, viruses, virus-infected host cells, or even tumor cells by pore formation. This pore formation kills the bacteria, virus-infected host cell (and immature virus) or tumor cell.
- C3a The complex nature of the complement system can be appreciated when following the fate of the split-conversion products of C3.
- One of the split products, C3a is a plasminogen and anaphylatoxin, which induces the release of histamine from basophilic cells, including tissue mast cells and basophilic granulocytes. Histamine, in turn, helps phagocytes to leave the blood vessels in order to arrive at the site of complement activation, i.e., the accumulation site of foreign material or immune complex.
- C3a is rapidly (in about 15 min.) inactivated by serum carboxypeptidases.
- the most prominent serum carboxypeptidase (sCP) in blood is the constitutively expressed sCP-N.
- sCP types are inducible and are less abundant than the N type.
- carboxypeptidases Upon the inactivation of C3a by carboxypeptidases, the C-terminal arginine is removed, resulting in the generation of C3adesArg.
- This compound is (probably identical to) an acylation-stimulating protein (ASP), a hormone that can stimulate fat accumulation in the body.
- ASP acylation-stimulating protein
- C3b and its inactivated form C3bi are opsonins, which means that they can bind covalently to sugar OH groups (via ester bonds) or protein NH 2 groups (via amide bonds) on material identified as ‘foreign’. In the case of such binding events, foreign material is also termed ‘substrate’.
- Other complement components can also function as opsonins, among these are other C3-derivatives and the complement component C4 (see below) and derivatives thereof.
- Opsonins promote the clearance of foreign material by the blood-based monocytes and tissue-based macrophages, both known as mononuclear phagocytes.
- the mononuclear phagocytic system is present in the liver, spleen, lymph nodes, or the affected tissue itself. These specialized cells carry specific complement receptors on their surface that can bind the opsonins. Known complement receptors on phagocytes are CR1, CR3, and possibly also CR4. CR1 is an exclusive receptor for C3b whereas CR3 and CR4 are also able to bind C3bi. In contrast to mononuclear phagocytes, polymorphonuclear phagocytes (PMNs) are relatively inefficient in eliminating foreign material, at least in the absence of antibodies.
- PMNs polymorphonuclear phagocytes
- immune complexes are eliminated by the mononuclear phagocytic system in the liver, spleen and bone, after erythrocyte-mediated transport via the blood stream.
- the erythrocytes carry a restricted number of CR1 molecules on their surface to which C3bi-coated immune complexes can adhere. This phenomenon is called ‘immune adherence’.
- Erythrocytes of non-primate species are CR1 negative and consequently do not mediate the transport of immune complexes to the liver, spleen and bone.
- the clearance of immune complexes involves antibody-mediated activation of the complement system.
- Microbial pathogens in the circulation are also cleared by the mononuclear phagocytic system, but only after MBL-mediated (‘lectin’ pathway) or antibody/C1-mediated (‘classical’ pathway) activation of complement components C4, C2, and C3. This process is known to involve erythrocyte-mediated clearance as well.
- the phenomenon of ‘immune adherence’ is one of importance to the present invention, as the present inventors have found that these CR1 complement receptors not only bind immune complexes or microbial pathogens, but also chylomicrons and other triglyceride-rich particles and their remnants. Based on this finding, new methods for the treatment, amelioration and/or prophylaxis of immune diseases are presented, which are based on intervention within particular lipid elements or modulation of the complement pathways involved.
- the complement system comprises several pathways each with a multitude of protein compounds, signaling molecules, receptors, regulators and activators. To appreciate the scope of the present invention, the various pathways of complement activation will be described in some more detail.
- MBL mannose-binding lectin
- MBL mannose-binding lectin
- MBL and the lung surfactant proteins A (LspA) and D (LspD) belongs to the family of the collagenous lectins (collectins).
- C1 the first component in the ‘classical’ pathway is a collectin-like activator of C4 and C2.
- MBL-associated proteins which are themselves esterases
- C4 and C2 become coordinately activated, ultimately leading to the generation of the active forms of the associated proteins, the LP-dependent C4, C2 and/or C3 convertases.
- These convertases which have C3, C4 and C2 as their natural substrates, generate essentially five products: C3b and C3a, C4bC2a and split products C4a and C2b.
- the C4b portion of C4bC2a binds covalently to its substrate (e.g. polysaccharides or (glyco) proteins on bacteria) via ester or amide bonds, and is therefore known as an opsonin.
- C4a and C2b are released in the fluid phase.
- Substrate-bound C4bC2a is the LP-dependent C3 convertase, causing the conversion of C3 into C3b and C3a.
- C4a is a plasminogen and anaphylatoxin (histamine liberator), whereas C2b has kinin-like activity.
- one of the MBL-associated proteins is capable of direct activation of C3.
- MBL recognizes foreign bodies by its 6 identical sugar-binding moieties with specificity for mannose, N-acetyl-glucosamine, and fucose. This makes sense, because microbial pathogens like, e.g., fungi, yeasts, and Mycobacteria, carry relatively high amounts of mannose, while peptidoglycans of Gram-positive bacteria contain N-acetyl-glucosamine as one of the major building blocks.
- microbial pathogens like, e.g., fungi, yeasts, and Mycobacteria
- the ‘alternative’ pathway (AP, also known as alternate pathway or alternative complement pathway), first described in 1956, was considered the most ancient complement activation route.
- the main function of this ‘alternative’ pathway is to increase (amplify) the number of C3-converting sites on the substrate of complement activation: the foreign body or the immune complex. This means that, once ‘non-self’ material has been identified by MBL and activation of the ‘lectin’ pathway has consequently taken place, the LP-dependent C3 convertase—C4bC2a present on the substrate—will be amplified by AP-dependent C3 convertases in the following manner (FIG.
- Substrate-bound C3b generated by the LP-dependent C3 convertase C4bC2a, will bind AP component factor B which, in turn, will be activated to Bb by AP component factor D (also known as adipsin) to form the AP-dependent C3 convertase (C3bBb).
- AP component factor D also known as adipsin
- the factor-B part loses a split product called Ba.
- the enzymic function of the AP-dependent C3 convertase is stabilized upon the binding of AP component ‘properdin’ (factor P), resulting in the AP-dependent C3 convertase complex C3bBbP.
- Split product Ba is a leukotaxin, which helps to direct the movement of phagocytes to the site of complement activation (primary inflammation site).
- C3b and inactivated C3b (C3bi) moieties on the substrate which promotes the recognition and clearance of foreign bodies and immune complexes by, predominantly, mononuclear phagocytes (monocytes/macrophages).
- the ‘classical’ pathway (CP) is generally considered the youngest complement activation route, since it is dependent on antibodies (IgM and IgG), which appeared relatively late in the phylogeny (from about 350 million years ago).
- the CP is very similar to, and therefore probably derived from the ancient ‘lectin’ pathway, since the first CP component (C1; consisting of a complex of the collectin-like C1 q and two MASP-like proteins called C1r and C1s) is both phenotypically and functionally very much related to the MBL/MASPs complex.
- the ‘classical’ pathway involves ‘lectin’ pathway complement components C4 and C2.
- C1(composed of C1q, C1r, and C1s) bound to IgM- or IgG-type immune complexes becomes coordinately activated to form a C1-esterase which has C4 and C2 as its natural substrates and which gives rise to the generation of CP-dependent C3 convertases, which are identical to LP-dependent C3 convertases (substrate-bound C4bC2a complexes).
- C4 exists in two isoforms known as C4A and C4B.
- C4A is involved in the clearance phenomenon, whereas C4B is mainly involved in the killing of bacteria and cell destruction (e.g. hemolysis).
- C4 is understood to relate to the C4A isoform unless otherwise stated.
- C3b molecule When a newly formed C3b molecule does not bind to the substrate directly, but to another substrate-bound C3 convertase (C4bC2a or C3bBbP), triple or quadruple complexes consisting of C4bC2aC3b or C3bBbC3bP are formed. These complexes have C5-converting activity indicating that they are able to split complement component C5 into C5b and C5a. This is the starting point of the so-called ‘terminal’or ‘lytic’ complement pathway. Like Ba, C5a is a leukotaxin, but more potent than Ba.
- C5b forms a complex with C6 and C7, the resultant of which is a soluble C5b-7 complex, which has affinity for membranous bilayers.
- complement component C8 Upon insertion into a membrane, e.g., a Gram-negative bacterium, complement component C8 will bind to the complex, which results in a new enzyme, the membrane-bound C9 polymerase (C5b-8).
- C5b-8 membrane-bound C9 polymerase
- 13 C9 molecules are polymerized, resulting in a cylindrical pore in the membrane that is under attack.
- the Gram-negative bacterium will either be killed or may survive the membrane attack.
- complement activation by homologous cells is heavily regulated by both cell-bound complement inhibitors and regulators in the fluid phase (e.g., serum or plasma).
- fluid phase e.g., serum or plasma
- ⁇ 2 -Macroglobulin ⁇ 2M
- serpines ⁇ 2 -Macroglobulin
- C4BP C4-binding protein
- Factor H also known as ⁇ 1H
- factor H-like molecules which act at the level of factor B binding to target-bound C3b (preventing the formation of AP-dependent C3 convertases)
- C3b inactivator factor I
- factor H acts in conjunction with factor H, to convert C3b into its enzymatically inactive, but still active as an opsonin, C3bi form.
- C1INH an inhibitor of complement component C1 which acts at the level of activated C1
- C1-esterase C1IN is also an inhibitor of other serine esterases such as kallikrein, the clotting factors XIa and XIIa, and the fibrinolysis product plasmin.
- Vitronectin S protein
- clusterin also known as apolipoprotein J or apo J. These proteins act at the level of C5b-7 complexes, preventing their insertion into bilayer membranes and inhibiting C9 polymerization and consequently, the lysis of bacteria, viruses and host cells.
- Complement receptor 1 which has factor-H-like co-enzyme function, as apposed to factor I.
- CR1 is present on phagocytes, platelets, and as a carrier protein on erythrocytes.
- Decay-accelerating factor which is also known as a cluster of differentiation protein CD55
- Sialic acid which acts at the level of the AP-dependent C3-convertase formation (similar to CD55 and CD46) and also on C9 polymerization.
- Bacterial lipopolysaccharides have recently been recognized as potent activators of the ‘lectin’pathway.
- ⁇ -glycyrrhetinic acid as a possible activator of C4
- the phytosterols including, for example, ⁇ -sitosterol, stigmasterol, and campesterol, have been shown to activate the ‘alternative’ pathway.
- Dextran sulphate functions as an acceptor site for the ‘alternative’ pathway regulatory protein factor H, and thus facilitates the ‘alternative’ pathway-mediated activation of C3 and subsequent deposition of C3b on a substrate.
- Lipid Metabolism The Physiology of Lipid Metabolism
- chylomicrons Under physiologic conditions, about 90% of the ingested fat (triglycerides) is taken up by the epithelial cells of the small intestine, resulting in the generation of intestinally-derived triglyceride-rich lipoproteins, called chylomicrons. These chylomicrons are translocated through the epithelial cells and delivered at the basolateral side to the sub-epithelial interstitium.
- apolipoprotein B48 apolipoprotein B48
- mannose 17.8%
- N-acetyl-glucosamine 16.8%
- galactose 13.4%)
- fucose 3.4%)
- Apo B48 is the 5′ splice product of a larger apob gene which—in human intestinal epithelial cells—is posttranscriptionally modified by a unique editing enzyme. This modification, or editing, results in the insertion of a premature stop codon, which results in the translation of only 48% of the apob mRNA.
- apob transcription in the liver results in the synthesis of full-length apo B100.
- This protein is the structural protein of the liver-derived triglyceride-rich particles known as VLDL (very low density lipoproteins) and their remnants (IDL's and LDL's).
- chylomicrons are collected in tissue fluid (lymph). Via lymph vessels, they are transported to subsequent draining lymph nodes and, through the thoracic duct and the left subclavian vein, they finally arrive in the blood stream. Once in the circulation, chylomicrons are rapidly converted into chylomicron remnants by the action of vascular-endothelium-associated lipoprotein lipase (LPL). The resulting chylomicron remnants are present in blood in different sizes.
- tissue fluid lymph
- LPL vascular-endothelium-associated lipoprotein lipase
- Chylomicrons and chylomicron remnants are efficiently cleared by the liver, where they can undergo bile-mediated excretion via the stool.
- the efficiency of the process of chylomicron and chylomicron-remnant targeting to the liver is not completely understood.
- the subsequent hepatic clearance of these triglyceride-rich particles has not been completely elucidated either. In the liver, it involves at least the activity of the hepatic triglyceride lipase (HTGL), interaction with specific apo E receptors, and non-receptor binding to the cellular surface in the hepatic space of Disse.
- HTGL hepatic triglyceride lipase
- LRP- ⁇ 2 M low-density-lipoprotein receptor-related protein
- chylomicron remnant receptor a parenchymal liver cell ‘chylomicron remnant receptor’
- asialoglycoprotein receptor the asialoglycoprotein receptor
- the lipolysis-stimulated receptor the LDL (low density lipoprotein) receptor.
- VLDL receptor a new member of the LDL receptor supergene family, which is not present in the liver, has been recognized as a physiological receptor for chylomicron remnants.
- VLDL very-low density lipoproteins
- FFA Free fatty acids
- adipocytes sub-endothelial fat cells
- ASP acylation-stimulating protein
- VLDL may become VLDL remnants, also called IDL (intermediate-density lipoproteins), by the lipolytic action of LPL, in this case, under the positive and negative control of two other apolipoproteins, apo CII and apo CIII [11], respectively.
- Apo E (formerly “Arginine Rich Apoprotein”) is one of the protein constituents of triglyceride-rich lipoproteins. Chylomicron remnants depend on apo E for their binding to the receptors, since the apo B48 structural protein does not contain the (carboxy-terminal) binding site for the LDL-receptor and ‘remnant receptor’. Apo E is synthesized by almost all tissues, but not by the epithelium of the intestine. The major organ responsible for apo E synthesis is the liver. As a result, chylomicrons receive apo E from HDL in the circulation, and therefore apo E is an exchangeable apoprotein.
- hepatocytes secrete apo E resulting in an enrichment of remnant particles, thereby facilitating their removal from the circulation.
- Apo E3 the most common
- apo E2 which results in a minority of the cases in dysbetalipoproteinemia in homozygotes
- apo E4 the highest affinity for binding to the receptors, while apo E2 exhibits the lowest affinity.
- Apo E4-individuals are highly responsive to dietary changes and cholesterol and fat enriched diets lead to higher plasma cholesterol concentrations in these individuals, due to down-regulation of LDL-receptors.
- IDLs are taken up by LDL-receptors in the liver and the lipoproteins are degraded and cholesterol is removed from the body by excretion into the bile.
- Chylomicron remnants are potentially atherogenic (atherosclerosis generating) particles due to their ability to directly induce foam-cell formation, without any modification.
- Low-density lipoprotein particles (LDL) in contrast, must be oxidized before they induce transformation of mononuclear phagocytes into foam cells.
- Mononuclear phagocytes have an LDL receptor by which they are able to bind, take up, internalize and subsequently degrade native LDL. As soon as the intracellular free cholesterol levels reach a threshold value the LDL receptors are down-regulated and the internalization process is stopped. Oxidized LDL particles, on the other hand, are taken up by ‘scavenger’ receptors, which are not down-regulated by cholesterol.
- apo CII deficiency apo CII deficiency
- LPL partial lipoprotein lipase
- HTGL hepatic triglyceride lipase
- FFA Free fatty acids
- the third finding relates to the glycosylation of apolipoprotein B, its kinship to MBL binding specificity and the insight that the complement-mediated lipid transport and transport of immune complexes may, thus, be modulated through interventions in the complement/lipid pathway and its individual elements or components.
- Such elements or components are understood to comprise all molecules, complexes and substances that play a role in the complement/lipid pathway.
- chylomicrons isolated from healthy individuals after an oral fat load, carry complement components C3 (i.e., the opsonins C3b and/or C3bi) (FIG. 4A). Thus, these chylomicrons initiate complement activation.
- C3 i.e., the opsonins C3b and/or C3bi
- chylomicrons initiate complement activation.
- chylomicrons also carry the ‘lectin’ pathway complement component mannose-binding lectin (MBL), and the terminal-complement-pathway inhibitors clusterin and vitronectin (FIGS. 4 B-E).
- chylomicrons activate the ‘lectin’ pathway (MBL-binding) which may ultimately lead to opsonization with C3b(i) [see ‘lectin’ pathway]) and to binding to the CR1 receptor of phagocytes and erythrocytes [see general description of complement system].
- MBL-binding MBL-binding
- C3b(i) C3b(i)
- erythrocytes C3b(i)
- the presence of clusterin and vitronectin indicates a capacity to inhibit the ‘terminal’ pathway of the human complement system.
- the pathway revealed by the present inventors provides an explanation for the observed complement activation and for a more complete physiological and immunological understanding of immunological diseases that are interconnected with lipid metabolism and/or underlying and/or related disease.
- the present inventors disclose that the prominent glycosylation sites of apolipoproteins B48 and B100, that are present as structural proteins on plasma chylomicrons and VLDL, respectively, match fully with the mannose, N-acetylglucosamine, and/or fucose binding specificity of MBL.
- triglyceride-rich particles (LDL, chylomicrons, VLDL, etc.) in the blood directly activate the complement system's ‘lectin’ pathway through binding of apolipoprotein B to MBL, thereby competing with immune complexes for binding on CR1 binding sites on the erythrocytes.
- apo B is potentially very harmful (note the existence of autoantibodies against the C3 convertases F-42 and C3 nephritic factor in patients with collagen diseases).
- the intrinsic complement activation nature of the structural apolipoprotein B molecules of triglyceride-rich particles is now predicted to be harmful for individuals with decreased serum levels of ‘terminal’pathway inhibitors vitronectin and/or clusterin, since such a situation will, subsequent to ‘lectin’ pathway activation, allow ‘terminal’ pathway activation to occur.
- Terminal’ pathway activation on triglyceride-rich particles may result in the release of atherogenic lipid material, particularly in patients with a genetic or acquired deficiency in the ‘terminal’ pathway regulators vitronectin or clusterin.
- the binding of the ‘terminal’ pathway inhibitors vitronectin and clusterin to chylomicrons can teleologically be explained in terms of protection from atherosclerosis.
- Such disorders may lead to a disease which may seem to be more related to an immunological disorder or malfunction such as auto-immune diseases, infectious diseases, neoplastic diseases and/or inflammatory diseases.
- Treatment, amelioration and/or prophylaxis as a benefit of the present invention occurs through modulation of the common pathway, e.g., by correction of disturbed complement function in the case of impaired complement-mediated lipid metabolism and will lead to an amelioration of lipid metabolism.
- impaired complement function in the case of impaired complement-mediated lipid metabolism
- impaired chylomicron remnant clearance is achieved.
- correction of disturbed complement function in case of impaired complement-mediated lipid metabolism, will result in an amelioration of diseases of the immune system, such as infectious, autoimmune, neoplastic or hematological diseases iterconnected with complement-dependent lipid metabolism.
- Disturbances of lipid metabolism and thus of the related immune response due to delayed or disturbed erythrocyte-dependent clearance of chylomicrons and/or VLDL may have a number of possible causes, which will determine the nature of the corrective measure. There may be:
- the activity of one or more elements of the lectin pathway and/or the alternative pathway of complement activation are modulated.
- Modulating according to the present invention should be understood as regulating, controlling, blocking, inhibiting, stimulating, activating, mimicking, bypassing, correcting, removing, washing, administering, adding, and/or substituting one or more elements in the pathway or, in more general terms, intervening in the pathway.
- the elements in the pathway comprise triglyceride-rich particles and/or their remnants and their constitutive proteins, complement proteins, complement activators, complement inhibitors, complement regulators and/or complement receptors.
- the modulating the activity of one or more elements is achieved through administration of a modulator.
- Modulators according to the invention are substances that can bring about a modulation in the complement/lipid pathway or the complement system and may comprise triglyceride-rich particles and/or remnants thereof and/or constitutive proteins thereof, complement proteins, complement activators, complement inhibitors such as serpines, factor H, factor I and/or C1INH, complement regulators such as ⁇ 2M, their metabolic precursors, the genes encoding the proteins and/or fragments thereof and they may be of physiologic (human or primate-derived), natural (e.g., plant-derived), recombinant, synthetic and/or semi-synthetic origin and in enriched, purified and/or chemically modified, complete and/or partial form, as metabolic precursor, as biochemically functional analogue or as functional equivalent of a (physiologic) modulator and/or derivatives thereof used alone or in combination.
- physiologic human or primate-derived
- natural e.g., plant-derived
- recombinant, synthetic and/or semi-synthetic origin
- Functional equivalents in the context of the present invention are understood to comprise molecules having at least one function of the original compound, preferably all functions of the original compound (although not necessarily to the same extent), more preferably chemically similar compounds, most preferably compounds differing by at most three groups which are not necessary for the relevant activity and/or function of the original compound.
- functional equivalents of complement factors are understood to comprise the split products of the factors.
- modulators may be MBL-replacement factors, which exhibit one or more functions of the mannose binding lectin such as binding to C3b or a mimetic thereof, and/or binding to the prominent apo B glycosylation sites or mimetics thereof
- MBL-replacement factor may comprise lectins derived from plants such as e.g., concanavalin A, peanut lectin, phytohemagglutinin or wheat-germ agglutinin, and may also comprise purified or enriched physiologic MBL or synthetic, or semi-synthetic mimetics of MBL and/or functional equivalents of MBL and may be used in an aspect of the invention relating to substituting for MBL deficiencies in the complement/lipid pathway.
- MBL replacement compounds also comprise lipid-C3 conjugates.
- modulators may comprise apo B-replacement factors, which may be functional equivalents of apoB that e.g., exhibit one or more functions of apolipoprotein B48 or B 100 such as binding to MBL or mimetics thereof and an ability to form a constituent of a lipoprotein or a mimetic thereof.
- Such an apo B-replacement factor may be chosen, for example, from physiologic apo B 48 or B100, natural lipo-oligosaccharides, lipopolysaccharides, lipidated oligosaccharides or polysaccharides, glycoproteins, ⁇ -glycyrrhetinic acid, chylomicron-bound sialic acid, phytosterols ( ⁇ -sitosterol, campesterol, and/or stigmasterol) and other amphiphilic (partially hydrophobic and partially hydrophilic) complement activator(s) (e.g., mannosylated, N-acetylglucosaminylated, and/or fucosylated phytosterols, or mannosylated, N-acetylglucosaminylated, and/or ficosylated membrane lipids, such as phosphoglycerides, glycolipids such as cerebroside or ganglioside, or sphingomyelin, phosphat
- suitable apo B-replacement factors comprise amphiphilic compounds or derivatives thereof wherein the hydrophilic part comprises one or more cationic, anionic and/or polar groups and wherein the hydrophobic part comprises one or more fatty-acid ester moieties.
- the fatty-acid ester moieties may comprise carbon chain lengths from 1 to 50 carbon atoms, they may be straight and/or branched and they may comprise saturated and/or unsaturated fatty acids.
- Preferred amphiphilic modulators additionally comprise one or more sugar moieties, such as N-acetylgalactosamine, galactose and/or sialic acid, which allow interaction with a lectin binding site.
- the one or more sugar moieties are mannose, N-acetylglucosamine, and/or fucose moieties that allow interaction with the lectin binding site of MBL.
- Suitable apo B replacement factors may comprise an IgA or IgD antibody, which is heavily mannosylated, N-acetylglucosaminylated, and/or fucosylated of either polyclonal or humanized monoclonal or combinatorial origin, directed towards one of the apolipoproteins of chylomicrons or very low-density lipoproteins (VLDL).
- IgA or IgD antibody which is heavily mannosylated, N-acetylglucosaminylated, and/or fucosylated of either polyclonal or humanized monoclonal or combinatorial origin, directed towards one of the apolipoproteins of chylomicrons or very low-density lipoproteins (VLDL).
- VLDL very low-density lipoproteins
- Such antibodies may also be bi-specific antibodies reactive towards both apoB and CR1, thereby being able to, e.g., create bonds between its two antigens
- modulators may be selected from the group comprising MBL and MBL-replacement factors, C4A and functional equivalents thereof, C4B and functional equivalents thereof, C2 and functional equivalents thereof, C3 and functional equivalents thereof, IgG- and IgM-antibodies raised against triglyceride-rich particles and LDL or parts thereof, C3adesArg, factor B and functional equivalents thereof, factor D and functional equivalents thereof, factor P and functional equivalents thereof, serum carboxypeptidases such as sCP-N and functional equivalents thereof, erythrocyte-bound CR1 and functional equivalents thereof, free CR1 and functional equivalents thereof, CR1 mimetics such as C3b antibodies, vitronectin and functional equivalents thereof, clusterin and functional equivalents thereof and apo B (48 and 100) and apo B replacement factors and esterases such as one of the MASP-proteins and functional equivalents thereof
- modulators may comprise antibodies.
- the modulator for the classical pathway is selected from the group of IgG and/or IgM antibodies.
- the group comprising apo B replacement factors also comprises an IgA or IgD antibody directed against an apo B lipoprotein, which antibody is heavily mannosylated, and/or heavily N-acetylglucosaminylated and/or heavily fucosylated.
- the modulator for the classical pathway is selected from the group of antibodies wherein the antibody comprises a polyclonal and/or humanized monoclonal and/or combinatorial antibody and/or bi-specific antibodies reactive towards both an apo B and CR1.
- Administration of a modulator may comprise oral administration, nasal administration, pulmonary administration, inhalation, anal and/or rectal administration, intravenous injection, intramuscular injection, intradermal injection, subcutaneous injection, mucous membrane diffusion, skin absorption, topical application, extracorporeal circulation-mediated administration and/or any other suitable administration route, single or in combination.
- Modulators according to the invention may be administered in pure form and/or diluted form, they may be in solid, semi-solid, crystalline and/or fluidic form, dissolved and/or dispersed alone or as a constituent of a fluid, a spray, a gel, an ointment, a tablet, a suppository, a capsule (synthetic, natural or viral), a powder, an (clinical) intralipid, a (clinical) food product, a (clinical) food additive, a lipidated vaccine for oral application, slow-release and/or direct release carrier that contains the modulator and/or any other suitable formulation for administration.
- modulators may be unlabeled or labeled with signal molecules or groups such as e.g., dyes, fluorochromes, radioactive atoms or groups, enzymes or luminescent molecules or groups.
- Apo B replacement factors according to the invention may be administered alone or in combination with other modulators in a natural, artificial or synthetic lipid carrier compound comprising lipoproteins, lipid micelles, lipid vesicles, artificial lipid bilayer membranes, chylomicrons, liposomes and/or other suitable and/or pharmaceutically accepted lipid substance.
- Clinical intralipids (fat emulsions) used in relation to the invention as parenteral feeding may comprise such a lipid carrier compound in combination with one or more modulators.
- the lipid carrier is selected from the group comprising mineral oil and natural oils, such as soy oil, sunflower oil, peanut oil, olive oil, palm oil and sesame oil and processed (purified and/or modified) versions thereof.
- the lipid carrier is (purified) olive oil.
- modulators in such a manner that the modulator is generated in-vivo, e.g., by gene therapy and/or by local administration of enzymes (e.g., apo B glycosylation enzymes) their encoding gene(s) and/or gene fragments.
- enzymes e.g., apo B glycosylation enzymes
- a method for modulating the activity of one or more elements in the complement/lipid pathway is used as a lymph-targeting, oro-mucosal adjuvant to induce enhanced mucosal antibody (IgA) responses, T-cell reactivity, and/or systemic T-cell and/or B-cell (IgM and/or IgG) antibody responses.
- IgA mucosal antibody
- T-cell reactivity T-cell reactivity
- IgM and/or IgG systemic T-cell and/or B-cell
- Complement consumption should be understood as complement entering the complement cascade thereby disappearing as free component.
- the complement components selected from the group comprising MBL, C4A, C4B, C2, factor B, C3adesArg, serum carboxypeptidase N, vitronectin, clusterin, and erythrocyte-bound complement receptor 1 (CR1)
- immune diseases infectious, autoimmune, or neoplastic
- lipid eliminating complement activation pathway can be diagnosed more adequately so that i.a., concomitant atherogenic processes are prevented.
- compositions for the treatment and/or prophylaxis of immune diseases associated with the complement/lipid pathway may be pharmaceutical compositions, in particular given together or in one composition comprising existing drugs for the treatment of immune diseases such as Tumor Necrosis Factor (TNF) and blockers thereof such as Humicade (CDP 571) or suppressors thereof such as thalomide (Thalidomide), interleukins such as IL-1, IL-12 and IL-15 and blockers or suppressors thereof, interferons such as IFNg and blockers or suppressors thereof, integrin and blockers or suppressors thereof, Intercellular Adhesion Molecules such as ICAM-1 and blockers or suppressors thereof and the like, probiotic strains of bacteria, additives for pharmaceutical compositions, active substances for pharmaceutical compositions, additives for clinical nutrition and/or regular food additives and that comprise modulators according to the invention, metabolic precursors of such modul
- compositions are used to modulate the activity of one or more elements of the complement/lipid pathway according to a method of the invention.
- the inventions provides for the use of a modulator according to the invention for the manufacture of a medicament, preferably for the treatment, amelioration and/or prophylaxis of a diseases of the immune system and/or an infectious, autoimmune, neoplastic or hematological disease interconnected with complement-mediated lipid metabolism and/or an underlying and/or related disease.
- Chylomicrons were isolated from plasma by ultra centrifugation and purified by column chromatography, in the following manner: For separation of lipoproteins, plasma samples were subjected to a single ultra-centrifugation step as described in Madsen et al. (12). Chylomicron (Sf>1000) and non-chylomicron (Sf ⁇ 1000) fractions were separated by flotation. The chylomicron fraction contained chylomicrons and large VLDL. The non-chylomicron fraction contained chylomicron remnants, small VLDL and its remnants, LDL, HDL and the remainder of the plasma proteins. Aliquots were stored at ⁇ 20° C. until use.
- C3 and MBL were also found in other lipoproteins isolated by one-step density gradient ultra centrifugation (Redgrave gradient) (IDL, LDL, HDL) in subjects fasting and postprandial after a fat challenge.
- VSB buffer a FITC-labeled anti-goat antibody solution
- Rabbit anti-goat Ig FITC DAKO 1:10 diluted in VSB buffer
- FITC-label was associated with the side-scattering particles (erythrocytes) only in the presence of the anti-apo B antibodies (FIG. 6, bottom panel), whereas no erythrocytes-associated FITC fluorescence could be detected in the case that incubation with anti-apo B antibodies was omitted from the analysis (negative control sample, FIG. 6, top panel). It was therefore concluded that apo B was associated with the erythrocytes in whole blood.
- subjects were only allowed to drink water or tea during the following 24 h.
- Orlistat a lipase inhibitor
- vitamin A-analoguesm Another series of compounds, namely vitamin A-analoguesm, were tested in 20 healthy volunteers in order to determine the CLiP stimulating potency of the compounds that had shown CLiP stimulation in vitro (Example 8). Twenty healthy volunteers were tested on 2 different occasions. Blood was drawn before and after ingestion of a standardized oral fat load with and without vitamin A (as a representative for this series of compounds) given to the participants in random order. Addition of vitamin A to the oral fat load resulted in a significantly higher postprandial plasma C3 increase, whereas the same amount of fat was ingested in both situations (FIG. 11A).
- Triglyceride-rich particles in plasma, chylomicrons and non-chylomicrons were determined by HPLC as described (14). TG and cholesterol were measured in duplicate by commercial calorimetric assay (GPO-PAP, and Monotest Cholesterol kit, Boehringer Mannheim) as described (14,23). Plasma apo B and apo AI were determined by immunoturbidimetry (23). Apo E genotype was determined as described (47-49). HDL2 and HDL3 cholesterol concentrations were determined by precipitation procedures as described (50). Complement factor 3 was measured immunoturbidimetry or nephelometrically. Acylation stimulating protein was determined by ELISA, as were factor B and D. Ketone bodies were measured by HPLC.
- UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-53.
Abstract
Description
- This application is a continuation-in-part of International Application Number PCT/NL01/00672, filed Sep. 12, 2001, designating the United States of America, International Publication No. WO 02/22160, published Mar. 21, 2002, in English.
- The invention relates to the diagnosis, prevention, and/or treatment of immunological diseases that are induced by disturbances in lipid metabolism.
- According to the classical view, immunological diseases and impaired lipid metabolism are two quite discrete disorders with distinct causalities. Auto-immune disease is an example of a disease of which the ethiology is difficult to assess. Both metabolic and inflammatory processes play a role and a relationship exists with microbiological factors.
- In discussing a possible relationship between infections with pathogenic micro-organisms, MBL (mannose-binding lectin) (an innate immune-defense plasma protein) deficiency and atherosclerosis, Madsen et al. [12] suggested that unexpected non-infective mechanisms are equally likely to play a role in the development of atherosclerosis as are the possibilities of a relationship with infectious microorganisms. The role of MBL in the immune system and the use of recombinant MBL in treating deficiencies in the immune system is known in the art (e.g., WO 0070043). The present invention teaches how lipid metabolism, complement activation, atherogenic processes and immune responses are physiologically related.
- The present inventors have elucidated a mechanism based on the relationship between lipid metabolism, immune adherence and immunological disorders. As a result of this new insight, a novel approach for the diagnosis, prevention, amelioration and/or therapy of immunological disorders that are induced by lipid metabolism and underlying and/or related diseases is presented, which comprises a method for the treatment and/or prophylaxis of immune diseases involving complement activation elements associated with disturbances in the complement/lipid pathway by modulating the activity of one or more elements in said pathway. By this method, a disease of the immune system and/or an infectious, autoimmune, neoplastic and/or hematological disease interconnected with complement-mediated lipid metabolism and/or an underlying and/or related disease may effectively be treated and/or its severity may be reduced. This new method may be implemented in a large range of conditions and in combination with current strategies to lower the occurrence and/or severity of immunological disorders, such as autoimmune disease and neoplastic disease.
- The present invention makes use of the surprising notion that the primary and most ancient function of the complement system is the transport and targeting of lipoproteins (i.e., chylomicrons, VLDL's, LDL's, and their remnants) to the liver, rather than its antimicrobial activity. Based on this new insight, novel preventive measures and treatment modulators of immune diseases involving complement activation pathway elements are introduced.
- In accordance with the invention, it has surprisingly been found that clearance of chylomicron remnants and in general clearance of all triglyceride-rich particles (chylomicrons, VLDL, IDL and their remnants) and LDL particles is positively regulated by the complement system; that is to say by the most ancient complement activation pathways, the ‘lectin’ and ‘alternative’ pathways. Delayed clearance of triglyceride-rich particles, in particular those containing apolipoprotein B as a structural protein is related to deficiencies in the ancient complement activation pathways. Moreover, in one embodiment the invention predicts that low serum levels of the intercellular matrix proteins vitronectin and/or clusterin, which function as regulators of the ‘terminal’ or ‘lytic’ pathways of complement, leads to decreased intravascular integrity of chylomicron remnants. Such a decreased integrity is typically atherogenic and can result in concomitant disease of a more immunological nature.
- Accordingly, the invention relates to the use of purified or enriched physiologic complement components, physiologic complement regulators and/or extrinsic complement modulators of natural (e.g. plant-derived), synthetic, or semi-synthetic origin in the prevention and/or treatment of atherosclerosis and underlying and/or related diseases by substituting for and/or at least diminishing deficiencies in the complement activation pathways.
- Because a thorough and mechanistic insight has now been achieved, the invention provides novel diagnostic tools and formulations of specific and highly effective primary and secondary prevention strategies for disturbances of immune functions influenced by the complement/lipid pathway. Dependent on what the relevant element, of an individual patient, in the specific pathways of the complement system is, a physician, based on the considerations of the invention, can modulate the activity of the complement system of the patient in order to prevent and/or treat manifestations of disease.
- The present invention provides new and improved methods of prevention, amelioration and/or treatment of disturbed immune functions which are interconnected with lipid metabolism and/or underlying or related diseases. The invention further provides new and improved methods of determining the occurrence (diagnosis) of disturbed immune functions interconnected with lipid metabolism and related diseases and teaches how to classify these diseases accordingly.
- The present invention provides for the coordinated design and discovery of new drugs, useful for the treatment of disturbed immune functions interconnected with lipid metabolism and related diseases. In addition, the present invention provides compositions comprising modulators of the complement activation pathways which can serve as a basis, or an ingredient of a pharmaceutical composition or a food product. Therefore, the present invention also relates to pharmaceutical products or food products that comprise such modulating compositions. The present invention provides the use of at least one complement factor or modulator for the manufacture of a medicament for the treatment, amelioration and/or prevention of disturbed immune functions interconnected with lipid metabolism or an underlying and/or related disease. Typically, such treatments would be combined with existing treatments of immune diseases. The invention may either inhibit the complement activation pathway or enhance it, depending on the disease to be treated, by modulating the lipid component of the pathway.
- FIG. 1 shows the complement system in schematic representation.
- FIG. 2 shows the two most ancient pathways of the complement system in a schematic representation.
- FIG. 3 shows the relationship between triglyceride rich particles (TRP), their remnants (TRP-R), the position of lipoprotein lipase (LPL), free fatty-acids (FFA), acylation-stimulating protein (ASP), several complement components (C3, factor B and factor D) in relation to triglyceride (TG) uptake by adipocytes and liver-derived very low density lipoproteins (VLDL).
- FIGS. 4A through E show the binding to chylomicrons of C3, MBL, clusterin and vitronectin as described in example 1.
- FIGS. 5A and B show the effect of immune adherence of triglyceride-rich particles to erythrocytes in blood after staining with Sudan Black as described in example 2.
- FIG. 6 shows the flow cytogram obtained after staining apo B on human erythrocytes as described in example 3.
- FIG. 7 shows the internalization of triglyceride-rich particles in a blood leukocyte as described in example 4.
- FIG. 8 shows the complement/lipid pathway in schematic representation.
- FIG. 9 shows the potency of different substances in the activation of complement in vitro.
- FIG. 10 shows the effects of glycosylated plantstanols on fasting triglycerides, plasma apoB and plasma cholesterol levels over a four month period in a patient with heterozygous Familial Hypercholesterolemia.
- FIG. 11A shows the effect of vitamin A on postprandial C3 plasma concentration after 2 h in healthy lean volunteers.
- FIG. 11B shows the effect of vitamin A on postprandial plasma triglycerid concentration after 2 h in healthy lean volunteers.
- In order to appreciate the importance of the invention, the inventors deem it necessary to explain the newly developed concept in much more detail. The surprisingly intricate relationship between the complement system and the clearance of chylomicron remnants unraveled by the inventors signifies a pathway not hitherto known. This unexpected finding gives rise to measures for treatment and prophylaxis of atherosclerosis that are themselves surprising, and that lead to the identification of additional risk factors and the development of novel therapeutic interventions which results in a significant reduction of total mortality due to CHD.
- I. The Complement System: General Description
- The complement system [9] is a complex signaling system comprising enzymes present in the blood. The complement system is involved in the early recognition and clearance from the circulation and tissues of foreign bodies and antigen-antibody complexes (also called immune complexes). Complement is recognized as an important, humoral defense system involved in the innate (nonspecific) recognition and elimination from the body of microbial invaders, other foreign particles or molecules, and antigen-antibody complexes.
- Upon the recognition of foreign material in the tissue or blood, the most crucial and abundant complement component, C3, is activated by C3 convertases. This activation triggers a cascade of events that ultimately leads to the clearance of the foreign material. C3, consisting of an α and β chain, is activated through a split-conversion into C3b and C3a (FIG. 1). C3a represents the N-terminus (77 amino acids) of the α chain and C3b represents the C-termini of the α and β chains. C3 convertases, of which various forms exist, can be generated through three different complement activation pathways (FIG. 1) and its synthesis is well regulated. The C3-convertase-generating pathways include, in order of descending evolutionary age, the so-called ‘lectin’ pathway (LP), the ‘alternative’ pathway (AP) which is also known as the ‘amplification loop’, and the relatively young ‘classical’ pathway (CP). During evolution, an additional system known as the ‘terminal’ or ‘lytic’ pathway has developed on top of the complement activation system, which can destabilize membranes of e.g. Gram-negative bacteria, viruses, virus-infected host cells, or even tumor cells by pore formation. This pore formation kills the bacteria, virus-infected host cell (and immature virus) or tumor cell. Phylogenetic studies have pointed out that the ‘lectin’ and ‘alternative’ pathways are by far the most ancient complement activation pathways (about 700 million years; FIG. 2), whereas the ‘classical’ and ‘lytic’ pathways are relatively young (400-350 million years).
- The complex nature of the complement system can be appreciated when following the fate of the split-conversion products of C3. One of the split products, C3a, is a plasminogen and anaphylatoxin, which induces the release of histamine from basophilic cells, including tissue mast cells and basophilic granulocytes. Histamine, in turn, helps phagocytes to leave the blood vessels in order to arrive at the site of complement activation, i.e., the accumulation site of foreign material or immune complex. In blood, C3a is rapidly (in about 15 min.) inactivated by serum carboxypeptidases. The most prominent serum carboxypeptidase (sCP) in blood is the constitutively expressed sCP-N. All other sCP types are inducible and are less abundant than the N type. Upon the inactivation of C3a by carboxypeptidases, the C-terminal arginine is removed, resulting in the generation of C3adesArg. This compound is (probably identical to) an acylation-stimulating protein (ASP), a hormone that can stimulate fat accumulation in the body.
- C3b and its inactivated form C3bi are opsonins, which means that they can bind covalently to sugar OH groups (via ester bonds) or protein NH2 groups (via amide bonds) on material identified as ‘foreign’. In the case of such binding events, foreign material is also termed ‘substrate’. Other complement components can also function as opsonins, among these are other C3-derivatives and the complement component C4 (see below) and derivatives thereof. Opsonins promote the clearance of foreign material by the blood-based monocytes and tissue-based macrophages, both known as mononuclear phagocytes. The mononuclear phagocytic system is present in the liver, spleen, lymph nodes, or the affected tissue itself. These specialized cells carry specific complement receptors on their surface that can bind the opsonins. Known complement receptors on phagocytes are CR1, CR3, and possibly also CR4. CR1 is an exclusive receptor for C3b whereas CR3 and CR4 are also able to bind C3bi. In contrast to mononuclear phagocytes, polymorphonuclear phagocytes (PMNs) are relatively inefficient in eliminating foreign material, at least in the absence of antibodies.
- In primates, immune complexes are eliminated by the mononuclear phagocytic system in the liver, spleen and bone, after erythrocyte-mediated transport via the blood stream. The erythrocytes carry a restricted number of CR1 molecules on their surface to which C3bi-coated immune complexes can adhere. This phenomenon is called ‘immune adherence’. Erythrocytes of non-primate species are CR1 negative and consequently do not mediate the transport of immune complexes to the liver, spleen and bone. In primates suffering from systemic autoimmune diseases and neoplastic diseases (cancer), the clearance of immune complexes involves antibody-mediated activation of the complement system.
- Microbial pathogens in the circulation are also cleared by the mononuclear phagocytic system, but only after MBL-mediated (‘lectin’ pathway) or antibody/C1-mediated (‘classical’ pathway) activation of complement components C4, C2, and C3. This process is known to involve erythrocyte-mediated clearance as well.
- The phenomenon of ‘immune adherence’ is one of importance to the present invention, as the present inventors have found that these CR1 complement receptors not only bind immune complexes or microbial pathogens, but also chylomicrons and other triglyceride-rich particles and their remnants. Based on this finding, new methods for the treatment, amelioration and/or prophylaxis of immune diseases are presented, which are based on intervention within particular lipid elements or modulation of the complement pathways involved.
- As mentioned, the complement system comprises several pathways each with a multitude of protein compounds, signaling molecules, receptors, regulators and activators. To appreciate the scope of the present invention, the various pathways of complement activation will be described in some more detail.
- II. The Complement System: The ‘Lectin’ Pathway
- Activation of the ‘lectin’ pathway (LP) starts with the recognition and binding of foreign bodies by a serum lectin, called mannose-binding lectin (MBL). MBL is a high-molecular-weight, sugar-binding protein, present in minute amounts (about 2 μg per ml) in blood plasma. MBL and the lung surfactant proteins A (LspA) and D (LspD), belongs to the family of the collagenous lectins (collectins). C1, the first component in the ‘classical’ pathway is a collectin-like activator of C4 and C2. Upon binding of MBL to foreign bodies, a number of MBL-associated proteins (MASPs—which are themselves esterases) become coordinately activated, ultimately leading to the generation of the active forms of the associated proteins, the LP-dependent C4, C2 and/or C3 convertases. These convertases, which have C3, C4 and C2 as their natural substrates, generate essentially five products: C3b and C3a, C4bC2a and split products C4a and C2b. Like C3b, the C4b portion of C4bC2a binds covalently to its substrate (e.g. polysaccharides or (glyco) proteins on bacteria) via ester or amide bonds, and is therefore known as an opsonin. The two split products, C4a and C2b, are released in the fluid phase. Substrate-bound C4bC2a is the LP-dependent C3 convertase, causing the conversion of C3 into C3b and C3a. Like C3a, C4a is a plasminogen and anaphylatoxin (histamine liberator), whereas C2b has kinin-like activity. Furthermore, one of the MBL-associated proteins is capable of direct activation of C3.
- MBL recognizes foreign bodies by its 6 identical sugar-binding moieties with specificity for mannose, N-acetyl-glucosamine, and fucose. This makes sense, because microbial pathogens like, e.g., fungi, yeasts, and Mycobacteria, carry relatively high amounts of mannose, while peptidoglycans of Gram-positive bacteria contain N-acetyl-glucosamine as one of the major building blocks.
- III. The Complement System: The ‘Alternative’ Pathway
- Until the discovery of the ‘lectin’ pathway in 1989, the ‘alternative’ pathway (AP, also known as alternate pathway or alternative complement pathway), first described in 1956, was considered the most ancient complement activation route. The main function of this ‘alternative’ pathway is to increase (amplify) the number of C3-converting sites on the substrate of complement activation: the foreign body or the immune complex. This means that, once ‘non-self’ material has been identified by MBL and activation of the ‘lectin’ pathway has consequently taken place, the LP-dependent C3 convertase—C4bC2a present on the substrate—will be amplified by AP-dependent C3 convertases in the following manner (FIG. 1): Substrate-bound C3b, generated by the LP-dependent C3 convertase C4bC2a, will bind AP component factor B which, in turn, will be activated to Bb by AP component factor D (also known as adipsin) to form the AP-dependent C3 convertase (C3bBb). Along with the formation of this new C3 convertase, the factor-B part loses a split product called Ba. The enzymic function of the AP-dependent C3 convertase is stabilized upon the binding of AP component ‘properdin’ (factor P), resulting in the AP-dependent C3 convertase complex C3bBbP. Split product Ba is a leukotaxin, which helps to direct the movement of phagocytes to the site of complement activation (primary inflammation site).
- The net result of AP activation is an increase in the number of C3b and inactivated C3b (C3bi) moieties on the substrate, which promotes the recognition and clearance of foreign bodies and immune complexes by, predominantly, mononuclear phagocytes (monocytes/macrophages).
- IV. The Complement System: The ‘Classical’ Pathway
- The ‘classical’ pathway (CP) is generally considered the youngest complement activation route, since it is dependent on antibodies (IgM and IgG), which appeared relatively late in the phylogeny (from about 350 million years ago). The CP is very similar to, and therefore probably derived from the ancient ‘lectin’ pathway, since the first CP component (C1; consisting of a complex of the collectin-like C1 q and two MASP-like proteins called C1r and C1s) is both phenotypically and functionally very much related to the MBL/MASPs complex. In addition, the ‘classical’ pathway involves ‘lectin’ pathway complement components C4 and C2. Like the sugar-bound MBL/MASPs complex, C1(composed of C1q, C1r, and C1s) bound to IgM- or IgG-type immune complexes becomes coordinately activated to form a C1-esterase which has C4 and C2 as its natural substrates and which gives rise to the generation of CP-dependent C3 convertases, which are identical to LP-dependent C3 convertases (substrate-bound C4bC2a complexes).
- C4 exists in two isoforms known as C4A and C4B. C4A is involved in the clearance phenomenon, whereas C4B is mainly involved in the killing of bacteria and cell destruction (e.g. hemolysis). In the present description, C4 is understood to relate to the C4A isoform unless otherwise stated.
- V. The Complement System: The Terminal or ‘Lytic’ Pathway
- When a newly formed C3b molecule does not bind to the substrate directly, but to another substrate-bound C3 convertase (C4bC2a or C3bBbP), triple or quadruple complexes consisting of C4bC2aC3b or C3bBbC3bP are formed. These complexes have C5-converting activity indicating that they are able to split complement component C5 into C5b and C5a. This is the starting point of the so-called ‘terminal’or ‘lytic’ complement pathway. Like Ba, C5a is a leukotaxin, but more potent than Ba. C5b forms a complex with C6 and C7, the resultant of which is a soluble C5b-7 complex, which has affinity for membranous bilayers. Upon insertion into a membrane, e.g., a Gram-negative bacterium, complement component C8 will bind to the complex, which results in a new enzyme, the membrane-bound C9 polymerase (C5b-8). Under the influence of a C5b-8 complex, 13 C9 molecules are polymerized, resulting in a cylindrical pore in the membrane that is under attack. Depending on the total number of membrane-bound poly-C9 pores, and on whether the bacterium is encapsulated, for example, by an outer lipoprotein membrane, or not, the Gram-negative bacterium will either be killed or may survive the membrane attack.
- V. The Complement System: Complement Regulation and Complement Regulators
- In order to prevent unwanted activation of the complement cascade, e.g., by cells of the body itself (homologous cells, in contrast to foreign or heterologous cells), complement activation by homologous cells is heavily regulated by both cell-bound complement inhibitors and regulators in the fluid phase (e.g., serum or plasma).
- V.1. The Most Important Soluble Regulators Are
- For the ‘lectin’pathway, the most important soluble regulators are α2-Macroglobulin (α2M), serpines and C4-binding protein (C4BP), which interfere with the formation of the LP-dependent C4/C2-convertase (activated MBL/MASPs complex) and the subsequent activation of C4 and C2.
- For the ‘alternative’ pathway, the most important soluble regulators are Factor H (also known as β1H) and factor H-like molecules, which act at the level of factor B binding to target-bound C3b (preventing the formation of AP-dependent C3 convertases), and C3b inactivator (factor I), which acts in conjunction with factor H, to convert C3b into its enzymatically inactive, but still active as an opsonin, C3bi form.
- For the ‘classical’ pathway, the most important soluble regulators are C1INH, an inhibitor of complement component C1, which acts at the level of activated C1, and the C1-esterase (C1IN is also an inhibitor of other serine esterases such as kallikrein, the clotting factors XIa and XIIa, and the fibrinolysis product plasmin).
- For the ‘lytic’ pathway, the most important soluble regulators are Vitronectin (S protein) and clusterin (also known as apolipoprotein J or apo J). These proteins act at the level of C5b-7 complexes, preventing their insertion into bilayer membranes and inhibiting C9 polymerization and consequently, the lysis of bacteria, viruses and host cells.
- V.2. Cell-Bound Complement Regulators Include:
- Complement receptor 1 (CR1) which has factor-H-like co-enzyme function, as apposed to factor I. CR1 is present on phagocytes, platelets, and as a carrier protein on erythrocytes.
- Decay-accelerating factor (DAF, which is also known as a cluster of differentiation protein CD55) and membrane cofactor protein (MCP=CD46), both of which act at the level of AP activation.
- The Homologous restriction factor with a 20-k molecular mass (HRF20=CD59) and HRF60, which both inhibit at the level of C9 polymerase (C5b-8) formation.
- Sialic acid, which acts at the level of the AP-dependent C3-convertase formation (similar to CD55 and CD46) and also on C9 polymerization.
- VI. The Complement System: Complement Activation and the Innate and Specific Immune System
- Apart from the physiological activating and regulatory complement components mentioned above, different substances of bacterial, plant, animal, or (semi)synthetic origin are known to either activate or inhibit the complement cascade(s). These components include, e.g., bacterial lipopolysaccharides, β-glycyrrhetinic acid, phytosterols, bovine conglutinin, and polymeric substances like dextran sulphate and glucans.
- Bacterial lipopolysaccharides have recently been recognized as potent activators of the ‘lectin’pathway. Likewise, β-glycyrrhetinic acid, as a possible activator of C4, was suggested to be able to activate the ‘lectin’ pathway. The phytosterols, including, for example, β-sitosterol, stigmasterol, and campesterol, have been shown to activate the ‘alternative’ pathway. Dextran sulphate functions as an acceptor site for the ‘alternative’ pathway regulatory protein factor H, and thus facilitates the ‘alternative’ pathway-mediated activation of C3 and subsequent deposition of C3b on a substrate.
- Based on their complement-activating capacity, a number of these substances, including bacterial lipopolysaccharides, dextran sulphates, and glucans, as well as lipidated muramyl-dipeptides and lipophilic quaternary ammonium compounds, like dimethyldioctadecyl ammonium bromide, show potent immunological adjuvant activity, which means that they are able to stimulate antigen-specific T- and B-cell responses.
- VII. Lipid Metabolism: The Physiology of Lipid Metabolism
- Under physiologic conditions, about 90% of the ingested fat (triglycerides) is taken up by the epithelial cells of the small intestine, resulting in the generation of intestinally-derived triglyceride-rich lipoproteins, called chylomicrons. These chylomicrons are translocated through the epithelial cells and delivered at the basolateral side to the sub-epithelial interstitium. The structure of chylomicrons is stabilized by a large, highly glycosylated protein, called apolipoprotein B48 (apo B48), of which the most dominant sugar residues are: mannose (17.8%), N-acetyl-glucosamine (16.8%), galactose (13.4%), and fucose (3.4%), which, in fact, fully matches with the binding specificities of MBL. Apo B48 is the 5′ splice product of a larger apob gene which—in human intestinal epithelial cells—is posttranscriptionally modified by a unique editing enzyme. This modification, or editing, results in the insertion of a premature stop codon, which results in the translation of only 48% of the apob mRNA. Since the human liver lacks the unique editing enzyme, apob transcription in the liver results in the synthesis of full-length apo B100. This protein is the structural protein of the liver-derived triglyceride-rich particles known as VLDL (very low density lipoproteins) and their remnants (IDL's and LDL's).
- From the sub-epithelial interstitium, chylomicrons are collected in tissue fluid (lymph). Via lymph vessels, they are transported to subsequent draining lymph nodes and, through the thoracic duct and the left subclavian vein, they finally arrive in the blood stream. Once in the circulation, chylomicrons are rapidly converted into chylomicron remnants by the action of vascular-endothelium-associated lipoprotein lipase (LPL). The resulting chylomicron remnants are present in blood in different sizes.
- Chylomicrons and chylomicron remnants are efficiently cleared by the liver, where they can undergo bile-mediated excretion via the stool. However, the efficiency of the process of chylomicron and chylomicron-remnant targeting to the liver is not completely understood. In addition, the subsequent hepatic clearance of these triglyceride-rich particles has not been completely elucidated either. In the liver, it involves at least the activity of the hepatic triglyceride lipase (HTGL), interaction with specific apo E receptors, and non-receptor binding to the cellular surface in the hepatic space of Disse. Several local receptors may be involved, including low-density-lipoprotein receptor-related protein, α2-Macroglobulin receptor (LRP-α2M), a parenchymal liver cell ‘chylomicron remnant receptor’, the asialoglycoprotein receptor, the lipolysis-stimulated receptor, and the LDL (low density lipoprotein) receptor. Recently, the VLDL receptor, a new member of the LDL receptor supergene family, which is not present in the liver, has been recognized as a physiological receptor for chylomicron remnants.
- Cholesterol, delivered to the liver by chylomicrons and chylomicron remnants, is largely re-secreted into the circulation after incorporation into very-low density lipoproteins (VLDL). This cholesterol is further employed by the adrenals and genitals as a skeleton for their steroid-hormone synthesis.
- Free fatty acids (FFA) arising from the breakdown of chylomicrons by the endothelial LPL are transported over the mucosa towards sub-endothelial fat cells (adipocytes) in which they become re-esterified into intracellular triglycerides (FIG. 3). The uptake and incorporation of FFA into adipocytes is under the positive control of a hormone called acylation-stimulating protein (ASP).
- Similarly to the hydrolysis of triglycerides in chylomicrons, VLDL may become VLDL remnants, also called IDL (intermediate-density lipoproteins), by the lipolytic action of LPL, in this case, under the positive and negative control of two other apolipoproteins, apo CII and apo CIII [11], respectively. IDLs are rich in apo E which functions as the ligand for the hepatic LDL receptor and ‘remnant-receptor’(=LRP, LDL-receptor-related protein which is a member of the LDL-receptor family comprising complement repeats and is possibly older than the LDL-receptor itself). Apo E (formerly “Arginine Rich Apoprotein”) is one of the protein constituents of triglyceride-rich lipoproteins. Chylomicron remnants depend on apo E for their binding to the receptors, since the apo B48 structural protein does not contain the (carboxy-terminal) binding site for the LDL-receptor and ‘remnant receptor’. Apo E is synthesized by almost all tissues, but not by the epithelium of the intestine. The major organ responsible for apo E synthesis is the liver. As a result, chylomicrons receive apo E from HDL in the circulation, and therefore apo E is an exchangeable apoprotein. In the liver-sinusoids, hepatocytes secrete apo E resulting in an enrichment of remnant particles, thereby facilitating their removal from the circulation. There are 3 major apo E isoforms which are genetically determined: Apo E3 (the most common), apo E2 (which results in a minority of the cases in dysbetalipoproteinemia in homozygotes), and apo E4. The latter has the highest affinity for binding to the receptors, while apo E2 exhibits the lowest affinity. Apo E4-individuals are highly responsive to dietary changes and cholesterol and fat enriched diets lead to higher plasma cholesterol concentrations in these individuals, due to down-regulation of LDL-receptors.
- Under physiological conditions, IDLs are taken up by LDL-receptors in the liver and the lipoproteins are degraded and cholesterol is removed from the body by excretion into the bile.
- Although much is known, the metabolic pathways of the intestinally- and liver-derived triglyceride-rich particles in blood, chylomicrons and VLDL, respectively, and their remnants, have hereto only been partially identified. It has been shown that these pathways comprise common elements and show a certain overlap. However, until the present invention, the very efficient targeting to the liver of chylomicrons and chylomicron remnants under physiological conditions and their clearance, was far from understood.
- VIII. Lipid Metabolism: Aberrant Lipid and/or Free-Fatty-Acid Metabolism
- Chylomicron remnants are potentially atherogenic (atherosclerosis generating) particles due to their ability to directly induce foam-cell formation, without any modification. Low-density lipoprotein particles (LDL), in contrast, must be oxidized before they induce transformation of mononuclear phagocytes into foam cells. Mononuclear phagocytes have an LDL receptor by which they are able to bind, take up, internalize and subsequently degrade native LDL. As soon as the intracellular free cholesterol levels reach a threshold value the LDL receptors are down-regulated and the internalization process is stopped. Oxidized LDL particles, on the other hand, are taken up by ‘scavenger’ receptors, which are not down-regulated by cholesterol.
- Since chylomicrons, VLDL, and their remnants, compete for the same metabolic pathways, patients with delayed or impaired remnant clearance may experience a temporary accumulation of chylomicrons and chylomicron remnants in the circulation, which obviously contributes to the process of atherogenesis, but also has consequences for the immunological component of the complement activation pathways. Such situations are likely to occur in patients with familial combined hyperlipidemia (FCHL), type-2 diabetes mellitus, insulin resistance, and obesity. Enhanced plasma VLDL levels in these situations are associated with delayed clearance of chylomicron remnants.
- Similar mechanisms are involved in conditions in which the clearance of remnant particles is impaired due to mutations in the apo E ligand gene (type III hyperlipidemia=familial dysbetalipoproteinemia), the LDL receptor (familial hypercholesterolemia; FH), familial defective apo B100 (FDB) and after menopause. In these conditions, which are all associated with the development of (premature) atherosclerosis, but would also have an influence on immune diseases, a delayed clearance of chylomicron remnants has been established due to an impaired binding to receptors in the liver. Other disorders associated with impaired remnant clearance are apo CII deficiency, (partial) lipoprotein lipase (LPL) deficiency, and hepatic triglyceride lipase (HTGL) deficiency. In these disorders, the conversion of triglyceride-rich particles into their remnants is delayed, leading to an accumulation in the circulation of triglyceride-rich particles of different sizes and triglyceride content.
- In many endocrinological disorders like hypothyroidism, growth hormone deficiency, hypercortisolism by endogenous or exogenous corticosteroids, and the postmenopausal state, a decreased clearance of chylomicron remnants has been established when compared with the control situation. Finally, in patients with premature atherosclerosis and normal fasting plasma lipids (40% of all patients with myocardial infarction below 60 years of age in males and beyond 65 years of age in females), chylomicron-remnant clearance is decreased. It has been hypothesized and it is widely accepted that this may be one of the important mechanisms underlying atherosclerosis in these groups of patients. For the first time it has now been established that it will also have an influence on the immunological part of the complement activation pathway.
- Free fatty acids (FFA) arising from the breakdown of chylomicrons by the endothelial lipoprotein lipase (LPL), and their uptake by the adipocytes, stimulates these adipocytes to synthesize complement component C3 and ‘alternative’ pathway components, factors B and D (note that in healthy individuals, there is a linear relationship between total body fat and C3 levels), and according to the invention complement activation occurs.
- Several important pathways involved in immune defense and lipid metabolism have been disclosed. However, a causal relationship between immune defense and lipid metabolism has not been established. Designing optimal treatment, ameliorating and/or prophylactic measures for disturbed immune functions of highly diverse nature and underlying and/or related diseases have thus far been impossible to achieve. It is now found by the present inventors that the existence of a pathway, that was hereto unknown, allows for the first time the development of such measures based on a more complete and physiological and immunological understanding of these diseases. The surprisingly intricate relationship between the complement system and the clearance of chylomicron remnants unraveled by the inventors demonstrates the presence of such a pathway, which is termed the lipid eliminating complement activation pathway or complement/lipid pathway.
- Due to this new finding the identification of additional risk factors, novel therapeutic interventions and pharmaceuticals and the treatment, amelioration and prophylaxis of disturbed immune functions, which are interconnected with impaired lipid metabolism, have now become available. This invention will result in a significant reduction in the severity of such immune diseases. The novel pathway was revealed, inter alia, by three independent findings. The first finding is that not only foreign bodies, but also chylomicrons can induce complement activation. The second finding is that chylomicrons bind to erythrocytes and that this binding utilized complement factors and as a result of which, lipid transport through the blood is complement and erythrocyte mediated. This led the inventors to the finding that immune complexes and complement-activated chylomicrons compete for binding sites on the erythrocyte. The third finding relates to the glycosylation of apolipoprotein B, its kinship to MBL binding specificity and the insight that the complement-mediated lipid transport and transport of immune complexes may, thus, be modulated through interventions in the complement/lipid pathway and its individual elements or components. Such elements or components are understood to comprise all molecules, complexes and substances that play a role in the complement/lipid pathway.
- It has now surprisingly been found that chylomicrons, isolated from healthy individuals after an oral fat load, carry complement components C3 (i.e., the opsonins C3b and/or C3bi) (FIG. 4A). Thus, these chylomicrons initiate complement activation. In addition, it was also surprisingly found that chylomicrons, isolated from healthy individuals after an oral fat load, also carry the ‘lectin’ pathway complement component mannose-binding lectin (MBL), and the terminal-complement-pathway inhibitors clusterin and vitronectin (FIGS.4B-E). Thus, chylomicrons activate the ‘lectin’ pathway (MBL-binding) which may ultimately lead to opsonization with C3b(i) [see ‘lectin’ pathway]) and to binding to the CR1 receptor of phagocytes and erythrocytes [see general description of complement system]. Furthermore, the presence of clusterin and vitronectin indicates a capacity to inhibit the ‘terminal’ pathway of the human complement system.
- It was found that virtually all erythrocytes of healthy volunteers carry chylomicrons and chylomicron remnants (FIG. 5A), whereas erythrocytes in the ‘fasting’ state carry considerably less chylomicrons and chylomicron remnants (FIG. 5B). This finding is in accordance with the new concept of an erythrocyte-mediated elimination of triglyceride-rich particles (and possibly also LDL particles) and complement-mediated lipid transport and can be interpreted in terms of immune adherence of remnant particles and targeting of lipids to the liver and spleen.
- The pathway revealed by the present inventors provides an explanation for the observed complement activation and for a more complete physiological and immunological understanding of immunological diseases that are interconnected with lipid metabolism and/or underlying and/or related disease. The present inventors disclose that the prominent glycosylation sites of apolipoproteins B48 and B100, that are present as structural proteins on plasma chylomicrons and VLDL, respectively, match fully with the mannose, N-acetylglucosamine, and/or fucose binding specificity of MBL. This means that triglyceride-rich particles (LDL, chylomicrons, VLDL, etc.) in the blood directly activate the complement system's ‘lectin’ pathway through binding of apolipoprotein B to MBL, thereby competing with immune complexes for binding on CR1 binding sites on the erythrocytes.
- As an intrinsic complement activator (of MBL), apo B is potentially very harmful (note the existence of autoantibodies against the C3 convertases F-42 and C3 nephritic factor in patients with collagen diseases). In particular, the intrinsic complement activation nature of the structural apolipoprotein B molecules of triglyceride-rich particles is now predicted to be harmful for individuals with decreased serum levels of ‘terminal’pathway inhibitors vitronectin and/or clusterin, since such a situation will, subsequent to ‘lectin’ pathway activation, allow ‘terminal’ pathway activation to occur. ‘Terminal’ pathway activation on triglyceride-rich particles may result in the release of atherogenic lipid material, particularly in patients with a genetic or acquired deficiency in the ‘terminal’ pathway regulators vitronectin or clusterin. The binding of the ‘terminal’ pathway inhibitors vitronectin and clusterin to chylomicrons can teleologically be explained in terms of protection from atherosclerosis.
- Combination of chylomicron (remnant)-induced complement activation of the ‘lectin’ pathway, the matching of glycosylation sites of apolipoproteins B48 and B100, the erythrocyte-mediated elimination of triglyceride-rich particles and competition between such particles and immune complexes for CR1-mediated binding on erythrocytes predicts that increased levels of triglyceride-rich particles in blood, as occurring in FCHL and other disorders associated with atherogenic disturbances of lipid metabolism, is due to sub optimal erythrocyte-dependent clearance of chylomicrons and/or VLDL.
- Also, disturbances in chylomicron- and/or VLDL- and/or chylomicron-remnant- and/or VLDL-remnant-mediated complement activation will lead to impaired lipid metabolism. Likewise, disturbances in the complement cascade, albeit subtle and e.g. acquired, may also lead to impaired lipid metabolism and, thereby to negative effects on the immune system.
- This bears considerable consequences for the treatment, amelioration and prophylaxis of all diseases related to the complement/lipid pathway, specifically those immune diseases interconnected with lipid metabolism.
- Diseases related to the disturbances in the complement/lipid pathway are immunological diseases that are interconnected with lipid metabolism and share an element of a common pathway. The similarity in their elimination pathways predicts that triglyceride-rich particles have to compete with soluble immune complexes and/or microbes for elimination sites on erythrocytes and in the liver and spleen, which would explain the disturbed lipid metabolism in e.g., septic shock. This bears considerable consequences for the treatment and prophylaxis of diseases such as, but not limited to, the auto-immune disorders, for example, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and paroxysmal nocturnal hemoglobinuria (PNH), virtually all infectious diseases and related disorders such as AIDS-related (secondary) lipodystrophy, septic shock, and multiple organ failure, inflammatory diseases such as Crohn's disease, inflammatory bowel syndrome (IBS), thermal injury including burns and frostbite, uveitis, psoriasis, asthma and neoplastic diseases such as cancer. This immunological aspect of the present invention holds consequences for improving the effectiveness of vaccination programs.
- Disorders directly related to the complement/lipid pathway comprise:
- disturbances in chylomicron-, chylomicron-remnant, VLDL- and/or VLDL-remnant-mediated complement activation;
- disturbances in the complement cascade itself;
- disturbances in erythrocyte-dependent chylomicron remnant and/or VLDL-remnant clearance;
- disturbances in the complement-mediated lipid metabolism; and
- disturbances in the regulation of lipid metabolism
- Such disorders may lead to a disease which may seem to be more related to an immunological disorder or malfunction such as auto-immune diseases, infectious diseases, neoplastic diseases and/or inflammatory diseases.
- Treatment, amelioration and/or prophylaxis as a benefit of the present invention occurs through modulation of the common pathway, e.g., by correction of disturbed complement function in the case of impaired complement-mediated lipid metabolism and will lead to an amelioration of lipid metabolism. By correcting the disturbed complement function, in the case of impaired complement-mediated lipid metabolism, an amelioration of disorders associated with impaired or disturbed chylomicron remnant clearance is achieved.
- Further, correction of disturbed complement function, in case of impaired complement-mediated lipid metabolism, will result in an amelioration of diseases of the immune system, such as infectious, autoimmune, neoplastic or hematological diseases iterconnected with complement-dependent lipid metabolism.
- Disturbances of lipid metabolism and thus of the related immune response due to delayed or disturbed erythrocyte-dependent clearance of chylomicrons and/or VLDL may have a number of possible causes, which will determine the nature of the corrective measure. There may be:
- congenital defects in glycosylation of apo B48 and/or apo B100;
- absolute (homozygous), or relative or acquired deficiencies of individual complement components of the ‘lectin’ and ‘alternative’ pathways (such deficiencies are known to occur for MBL [9% of the population], C4A [the defective gene frequency is 10-13% of the population], C4B [the defective gene frequency is 7-18% of the population], C2 [rare], C3 [rare], factor B [rare] and factor D [rare]);
- deficiencies of serum carboxypeptidases (sCP) which exclude the conversion of C3a into C3adesArg [incidence unknown];
- absolute [rare] or relative [quite common] deficiencies of complement receptor 1 (CR1) on erythrocytes as occurring in some patients with systemic lupus erythematosus (SLE);
- deficiencies of terminal-pathway regulator vitronectin [4% of the population], which may lead to the lysis of triglyceride-rich particles resulting in unwanted deposition of lipids; or
- decreased serum levels of clusterin in association with exacerbations of SLE or with circulating immune complexes accompanying neoplastic diseases [deficiencies in clusterin are rare; <<1% of the population].
- The incidence of serious cardiovascular disease [37% in 1997] in the Netherlands, expressed as percentage of total numbers of fatal cases per year, matches well with the combined figures for MBL, C4A, C4B, vitronectin, and clusterin deficiencies, corrected for the incidence of double and triple deficiencies.
- It is one embodiment of the present invention to provide a method for the treatment, amelioration and/or prophylaxis of immune diseases associated with the complement/lipid pathway by modulating the activity of one or more elements in said pathway.
- In another embodiment according to the invention the activity of one or more elements of the lectin pathway and/or the alternative pathway of complement activation are modulated.
- Modulating according to the present invention should be understood as regulating, controlling, blocking, inhibiting, stimulating, activating, mimicking, bypassing, correcting, removing, washing, administering, adding, and/or substituting one or more elements in the pathway or, in more general terms, intervening in the pathway.
- It is an aspect of the invention that the elements in the pathway comprise triglyceride-rich particles and/or their remnants and their constitutive proteins, complement proteins, complement activators, complement inhibitors, complement regulators and/or complement receptors.
- It is one embodiment of the present invention that the modulating the activity of one or more elements is achieved through administration of a modulator.
- Modulators according to the invention are substances that can bring about a modulation in the complement/lipid pathway or the complement system and may comprise triglyceride-rich particles and/or remnants thereof and/or constitutive proteins thereof, complement proteins, complement activators, complement inhibitors such as serpines, factor H, factor I and/or C1INH, complement regulators such as α2M, their metabolic precursors, the genes encoding the proteins and/or fragments thereof and they may be of physiologic (human or primate-derived), natural (e.g., plant-derived), recombinant, synthetic and/or semi-synthetic origin and in enriched, purified and/or chemically modified, complete and/or partial form, as metabolic precursor, as biochemically functional analogue or as functional equivalent of a (physiologic) modulator and/or derivatives thereof used alone or in combination.
- Functional equivalents in the context of the present invention are understood to comprise molecules having at least one function of the original compound, preferably all functions of the original compound (although not necessarily to the same extent), more preferably chemically similar compounds, most preferably compounds differing by at most three groups which are not necessary for the relevant activity and/or function of the original compound. In the context of the present invention, functional equivalents of complement factors are understood to comprise the split products of the factors.
- In a preferred embodiment according to the invention, modulators may be MBL-replacement factors, which exhibit one or more functions of the mannose binding lectin such as binding to C3b or a mimetic thereof, and/or binding to the prominent apo B glycosylation sites or mimetics thereof Such an MBL-replacement factor may comprise lectins derived from plants such as e.g., concanavalin A, peanut lectin, phytohemagglutinin or wheat-germ agglutinin, and may also comprise purified or enriched physiologic MBL or synthetic, or semi-synthetic mimetics of MBL and/or functional equivalents of MBL and may be used in an aspect of the invention relating to substituting for MBL deficiencies in the complement/lipid pathway. MBL replacement compounds also comprise lipid-C3 conjugates.
- In another preferred embodiment according to the invention, modulators may comprise apo B-replacement factors, which may be functional equivalents of apoB that e.g., exhibit one or more functions of apolipoprotein B48 or
B 100 such as binding to MBL or mimetics thereof and an ability to form a constituent of a lipoprotein or a mimetic thereof. Such an apo B-replacement factor may be chosen, for example, from physiologic apo B 48 or B100, natural lipo-oligosaccharides, lipopolysaccharides, lipidated oligosaccharides or polysaccharides, glycoproteins, β-glycyrrhetinic acid, chylomicron-bound sialic acid, phytosterols (β-sitosterol, campesterol, and/or stigmasterol) and other amphiphilic (partially hydrophobic and partially hydrophilic) complement activator(s) (e.g., mannosylated, N-acetylglucosaminylated, and/or fucosylated phytosterols, or mannosylated, N-acetylglucosaminylated, and/or ficosylated membrane lipids, such as phosphoglycerides, glycolipids such as cerebroside or ganglioside, or sphingomyelin, phosphatidyl choline, phosphatidyl serine, phosphatidyl ethanolamine, phosphatidyl inositol, diphosphatidyl glycerol or sphingosine), stanols (glycosylated and non-glycosylated), lipidated dextran sulphate(s), (lipo)glucan(s), lipidated tertiary or quaternary ammonium compounds, sialylated glycolipids, combinations thereof and single and/or combined related substances. In general, suitable apo B-replacement factors comprise amphiphilic compounds or derivatives thereof wherein the hydrophilic part comprises one or more cationic, anionic and/or polar groups and wherein the hydrophobic part comprises one or more fatty-acid ester moieties. The fatty-acid ester moieties may comprise carbon chain lengths from 1 to 50 carbon atoms, they may be straight and/or branched and they may comprise saturated and/or unsaturated fatty acids. - Preferred amphiphilic modulators additionally comprise one or more sugar moieties, such as N-acetylgalactosamine, galactose and/or sialic acid, which allow interaction with a lectin binding site. In another embodiment according to the invention, the one or more sugar moieties are mannose, N-acetylglucosamine, and/or fucose moieties that allow interaction with the lectin binding site of MBL. Other suitable apo B replacement factors may comprise an IgA or IgD antibody, which is heavily mannosylated, N-acetylglucosaminylated, and/or fucosylated of either polyclonal or humanized monoclonal or combinatorial origin, directed towards one of the apolipoproteins of chylomicrons or very low-density lipoproteins (VLDL). Such antibodies may also be bi-specific antibodies reactive towards both apoB and CR1, thereby being able to, e.g., create bonds between its two antigens.
- In another embodiment according to the invention, modulators may be selected from the group comprising MBL and MBL-replacement factors, C4A and functional equivalents thereof, C4B and functional equivalents thereof, C2 and functional equivalents thereof, C3 and functional equivalents thereof, IgG- and IgM-antibodies raised against triglyceride-rich particles and LDL or parts thereof, C3adesArg, factor B and functional equivalents thereof, factor D and functional equivalents thereof, factor P and functional equivalents thereof, serum carboxypeptidases such as sCP-N and functional equivalents thereof, erythrocyte-bound CR1 and functional equivalents thereof, free CR1 and functional equivalents thereof, CR1 mimetics such as C3b antibodies, vitronectin and functional equivalents thereof, clusterin and functional equivalents thereof and apo B (48 and 100) and apo B replacement factors and esterases such as one of the MASP-proteins and functional equivalents thereof
- In another preferred embodiment according to the invention, modulators may comprise antibodies. In a more preferred embodiment, the modulator for the classical pathway is selected from the group of IgG and/or IgM antibodies.
- In another embodiment, the group comprising apo B replacement factors also comprises an IgA or IgD antibody directed against an apo B lipoprotein, which antibody is heavily mannosylated, and/or heavily N-acetylglucosaminylated and/or heavily fucosylated. In another embodiment, the modulator for the classical pathway is selected from the group of antibodies wherein the antibody comprises a polyclonal and/or humanized monoclonal and/or combinatorial antibody and/or bi-specific antibodies reactive towards both an apo B and CR1.
- Administration of a modulator may comprise oral administration, nasal administration, pulmonary administration, inhalation, anal and/or rectal administration, intravenous injection, intramuscular injection, intradermal injection, subcutaneous injection, mucous membrane diffusion, skin absorption, topical application, extracorporeal circulation-mediated administration and/or any other suitable administration route, single or in combination.
- Modulators according to the invention may be administered in pure form and/or diluted form, they may be in solid, semi-solid, crystalline and/or fluidic form, dissolved and/or dispersed alone or as a constituent of a fluid, a spray, a gel, an ointment, a tablet, a suppository, a capsule (synthetic, natural or viral), a powder, an (clinical) intralipid, a (clinical) food product, a (clinical) food additive, a lipidated vaccine for oral application, slow-release and/or direct release carrier that contains the modulator and/or any other suitable formulation for administration. Furthermore, modulators may be unlabeled or labeled with signal molecules or groups such as e.g., dyes, fluorochromes, radioactive atoms or groups, enzymes or luminescent molecules or groups.
- Apo B replacement factors according to the invention may be administered alone or in combination with other modulators in a natural, artificial or synthetic lipid carrier compound comprising lipoproteins, lipid micelles, lipid vesicles, artificial lipid bilayer membranes, chylomicrons, liposomes and/or other suitable and/or pharmaceutically accepted lipid substance. Clinical intralipids (fat emulsions) used in relation to the invention as parenteral feeding may comprise such a lipid carrier compound in combination with one or more modulators. In a preferred embodiment of such a parenteral feeding, the lipid carrier is selected from the group comprising mineral oil and natural oils, such as soy oil, sunflower oil, peanut oil, olive oil, palm oil and sesame oil and processed (purified and/or modified) versions thereof. In another embodiment of such a parenteral feeding, the lipid carrier is (purified) olive oil.
- It is another embodiment of the present invention to administer modulators in such a manner that the modulator is generated in-vivo, e.g., by gene therapy and/or by local administration of enzymes (e.g., apo B glycosylation enzymes) their encoding gene(s) and/or gene fragments.
- It is a further embodiment of the present invention to use a method for modulating the activity of one or more elements in the complement/lipid pathway for the treatment and/or prophylaxis of immune diseases associated with complement-mediated lipid metabolism.
- It is a further embodiment of the present invention to use a method for modulating the activity of one or more elements in the complement/lipid pathway to prevent atherogenic processes of immune diseases that (partially) share the lipid eliminating complement activation pathway.
- It is a further embodiment of the present invention to use a method for modulating the activity of one or more elements in the complement/lipid pathway to efficiently manipulate the immune system.
- It is a further embodiment of the present invention to use a method for modulating the activity of one or more elements in the complement/lipid pathway to achieve optimum systemic immunosuppression by lipophilic immunosuppressants.
- It is a further embodiment of the present invention to use a method for modulating the activity of one or more elements in the complement/lipid pathway to achieve optimum oral immunization. In another embodiment, a method for modulating the activity of one or more elements in the complement/lipid pathway is used as a lymph-targeting, oro-mucosal adjuvant to induce enhanced mucosal antibody (IgA) responses, T-cell reactivity, and/or systemic T-cell and/or B-cell (IgM and/or IgG) antibody responses.
- It is an embodiment of the present invention to provide prophylactic measures for immune diseases associated with the complement/lipid pathway by providing improved methods for diagnosing such diseases.
- It is one embodiment of the present invention to estimate the potential of plant-derived, synthetic, or semi synthetic substances for use in the treatment of immune diseases by determining their complement activation and/or consumption activity. Complement consumption should be understood as complement entering the complement cascade thereby disappearing as free component.
- It is another embodiment of the present invention to estimate one or more of the complement components selected from the group comprising MBL, C4A, C4B, C2, factor B, C3adesArg, serum carboxypeptidase N, vitronectin, clusterin, and erythrocyte-bound complement receptor 1 (CR1), in blood, blood serum and/or blood plasma of a patient in order to establish the underlying or related defect of his/her disease.
- It is a further embodiment of the present invention that immune diseases (infectious, autoimmune, or neoplastic) that may (partially) occupy the lipid eliminating complement activation pathway can be diagnosed more adequately so that i.a., concomitant atherogenic processes are prevented.
- It is a further embodiment of the present invention to provide compositions for the treatment and/or prophylaxis of immune diseases associated with the complement/lipid pathway. Compositions according to such an embodiment of the present invention may be pharmaceutical compositions, in particular given together or in one composition comprising existing drugs for the treatment of immune diseases such as Tumor Necrosis Factor (TNF) and blockers thereof such as Humicade (CDP 571) or suppressors thereof such as thalomide (Thalidomide), interleukins such as IL-1, IL-12 and IL-15 and blockers or suppressors thereof, interferons such as IFNg and blockers or suppressors thereof, integrin and blockers or suppressors thereof, Intercellular Adhesion Molecules such as ICAM-1 and blockers or suppressors thereof and the like, probiotic strains of bacteria, additives for pharmaceutical compositions, active substances for pharmaceutical compositions, additives for clinical nutrition and/or regular food additives and that comprise modulators according to the invention, metabolic precursors of such modulators, biochemically functional analogues, functional equivalents and/or derivatives of such modulators with or without expedients such as fillers, binders, other complement activators such as vitamin A, thickening agents, preservatives, lubricants, emulsifiers, emulgators, and/or stabilizers.
- It is an embodiment of the present invention that such compositions are used to modulate the activity of one or more elements of the complement/lipid pathway according to a method of the invention.
- Also, the inventions provides for the use of a modulator according to the invention for the manufacture of a medicament, preferably for the treatment, amelioration and/or prophylaxis of a diseases of the immune system and/or an infectious, autoimmune, neoplastic or hematological disease interconnected with complement-mediated lipid metabolism and/or an underlying and/or related disease.
- Complement Components Associated with Chylomicrons.
- Experimental procedure: Chylomicrons were isolated from plasma by ultra centrifugation and purified by column chromatography, in the following manner: For separation of lipoproteins, plasma samples were subjected to a single ultra-centrifugation step as described in Madsen et al. (12). Chylomicron (Sf>1000) and non-chylomicron (Sf<1000) fractions were separated by flotation. The chylomicron fraction contained chylomicrons and large VLDL. The non-chylomicron fraction contained chylomicron remnants, small VLDL and its remnants, LDL, HDL and the remainder of the plasma proteins. Aliquots were stored at −20° C. until use. In the fractions containing large chylomicrons (large triglyceride-rich particles) complement components C3, MBL, clusterin (exp. 1), clusterin (exp. 2) and vitronectin were measured by competitive ELISA using the purified proteins and MBL- and C3-specific polyclonal and clusterin-specific monoclonal-antibodies G7* and EB-8* and vitronectin-specific monoclonal antibody MO-24* as reagents. The presence of the complement factors could consistently be demonstrated in
fractions 13 through 20 (see FIGS. 4A-E). In addition, C3 and MBL were also found in other lipoproteins isolated by one-step density gradient ultra centrifugation (Redgrave gradient) (IDL, LDL, HDL) in subjects fasting and postprandial after a fat challenge. - Adherence of Triglyceride-Rich Particles to Erythrocytes in Whole Blood.
- Experimental procedure: To observe adherence of triglyceride-rich particles to erythrocytes in whole blood, Sudan Black staining of erythrocytes in whole blood was performed. In this procedure, blood smears were prepared and Sudan Black staining was performed with a filtered and saturated solution of Sudan Black in 80% ethanol (4 grams of Sudan Black B, Electran in 200 ml of 80% ethanol) by the following procedure. The blood film on the glass slide was fixed by heat fixation (3× through a flame). The slide was soaked in Sudan Black solution for 3 min. after which the slide was rinsed with 80% ethanol. The preparation was re-hydrated by a graded ethanol series (1 min. 40% ethanol, 1 min. 20% ethanol, 1 min. demineralized water). Excess water was shaken off and the slides were dried to air. Microscopic examination of the slides revealed that virtually all erythrocytes of healthy volunteers carried chylomicrons and
chylomicron remnants 4 hours after an oral fat intake (FIG. 5A), whereas erythrocytes in the ‘fasting’ state carried considerably less such particles (FIG. 5B). - Measurement of Erythrocyte-Bound-apo B Containing Lipoproteins by Flow Cytometry.
- Experimental procedure: Full capillary blood was drawn from non-fasting healthy subjects by capillary punction. The blood was washed 3 times in 10 ml of VSB buffer (Veronal Saline Buffer) by centrifugation (3,000 rpm, 10 min., 20° C.) and the cell count was adjusted to 1.5×108/ml with VSB buffer. A volume of 50 μl of the sample was pelleted and the pellet was re-suspended in 50 μl of a goat raised anti-human apo B polyclonal antibody solution (Chemicon 1:25 diluted in VSB buffer). After a 30 min. incubation of the sample at room temperature (RT) the cells were washed twice in 1 ml. of VSB buffer. The cells were pelleted and re-suspended in 50 μl of a FITC-labeled anti-goat antibody solution (Rabbit anti-goat Ig FITC, DAKO 1:10 diluted in VSB buffer). After a 30 min. incubation of the sample at RT the cells were washed twice in 1 ml. of VSB buffer, pelleted, resuspended in 0.5 ml. of VSB buffer and analyzed by flow cytometry (10,000 cells were counted). Erythrocytes were gated on forward and side scatter. It could be demonstrated that the FITC-label was associated with the side-scattering particles (erythrocytes) only in the presence of the anti-apo B antibodies (FIG. 6, bottom panel), whereas no erythrocytes-associated FITC fluorescence could be detected in the case that incubation with anti-apo B antibodies was omitted from the analysis (negative control sample, FIG. 6, top panel). It was therefore concluded that apo B was associated with the erythrocytes in whole blood.
- Binding and Internalization of Chylomicron Remnants by Leukocytes in the Blood (In Vivo).
- Experimental procedure: Fasting venous blood was drawn and Sudan Black staining as described in example 2 was carried out (left panel of FIG. 7). In the right panel of FIG. 7, venous blood of the same healthy volunteer was drawn 4 hours after administration of a standardized oral fat load. In the oral RP-fat loading test, cream is used as fat source; this is a 40% (w/v) fat emulsion with a P/S ratio of 0.06, which contains 0.001% (w/v) cholesterol and 2.8% (w/v) carbohydrates. After an overnight fast of 12 h, the subjects ingest the fresh cream, to which 120.000 U of aqueous RP (Retinyl palmitate =vitamin A) had been added 18 h before the test, in a dose of 50 g per m2 body surface. After the ingestion of the fat load, subjects were only allowed to drink water or tea during the following 24 h. Peripheral blood samples were obtained in sodium EDTA (2 mg/ml) before (T=0), at hourly intervals up to 10 h and at 12 and 24 h after the meal. Tubes were protected against light by aluminum foil and centrifuged immediately for 15 min at 800×g at 4° C. Blood samples for FFA measurement were chilled and a lipase inhibitor (Orlistat) was added in order to block in-vitro lipolysis.
- Increased leukocyte concentrations in the postprandial situation are involved in the process of atherosclerosis (novel finding). After having taken up surface fragments from triglyceride-rich particles or whole remnant particles (see FIG. 1), neutrophilic granulocytes become activated and induce a pro-inflammatory response which is the first step in the generation of atherosclerosis and endothelial damage.
- Magnitude and Time-Dependency of Increase of Complement Component 3 (C3) in the Postprandial Period.
- Experimental procedure: Standardized oral fat loading tests (oral RP fat loading test) were performed in volunteers and patients and plasma C3 levels were determined nephelometrically at regular intervals.
Complement component 3 was measured by nephelometry (Dade Behring Nephelometry type II). Maximal postprandial C3 concentrations were in most cases found after 2 hrs. (data not shown). This is consistent with the concept of chylomicron-driven complement activation (MBL mediated) followed by a compensatory C3 synthesis in-vivo. We therefore conclude that complement activation occurs in vivo during postprandial lipemia (high blood lipid concentrations). - Binding and Internalization of Chylomicron Remnants by Leukocytes in the Blood (In Vitro).
- Experimental procedure: In vitro incubations of chylomicron remnants with isolated human leukocytes were performed by methods described in example 3. Internalization of remnants in leukocytes was observed (data not shown).
- Assay for Complement-Activation cq. Complement-Consumption by Drugs/Food Components Intended for Application in Atherosclerosis or Clinical Nutrition.
- Experimental procedure: In microtiter plates, one ‘classical’ pathway unit of serum or one ‘alternative’ pathway unit of serum was incubated for 0.5 hrs. with a dilution series of the substance to be investigated. In order to do so, the substance of interest is suspended in micellar form. After incubation, residual classical and alternative complement activities are estimated by conventional techniques (Klerx J. P. A. M., C. J. Beukelman, H. Van Dijk and J. M. N. Willers (1983) J. Immunol. Lett. 63:215-220; Van Dijk H, P. M. Rademaker and J. M. N. Willers (1985) J. Immunol. Meth. 85: 233-244). The degree of complement consumption is a measure of complement activation by the components. A large number of compounds were identified by this in-vitro assay for application in atherosclerosis or clinical nutrition.
- MBL-Dependent Complement Activation by Chylomicrons in Human Serum.
- Experimental procedure: Chylomicrons were isolated from human serum by ultra centrifugation and purified by column chromatography. The purified chylomicron fractions were added to MBL-positive serum (from healthy human subjects) and MBL-negative serum (from MBL-deficient human subjects) and purified heterologous chicken erythrocytes were added. Complement activation was allowed to occur at 37° C. for 45 min. after which, the extend of hemolysis was evaluated by spectrophotometrical determination of hemoglobin levels in serum supernatants. It was found that hemolysis of heterologous erythrocytes was extensive in the case that an MBL-positive serum was used, whereas hemolysis was virtually absent in the case of an MBL-negative serum (data not shown). This demonstrated that chylomicrons can bring about complement activation in human serum in an MBL-dependent manner.
- Using the MBL in-vitro assay, we identified, as an example, the components from olive oil and soy oil inducing Complement Lipid Pathway (CliP)-activation.
- The results are summarized in FIG. 9.
- From these results, two compounds were selected which show strong CLiP-induction and which are known to be safe to be administered to human (thanks to other clinical use), specifically (i) glycosylated plant sterols and (ii) vitamin A.
- Postprandial C3 Buildup.
- Experimental procedure: Full capillary blood was draw from healthy subjects and the C3 levels were determined together with the leukocyte count. Postprandial (situation in blood after a meal) leukocyte increase and activation was associated with postprandial complement C3 increase. In the early postprandial phase (<4 hr) predominantly neutrophilic granulocytes were observed, whereas between 4 and 10 hrs into the postprandial period, an increase of lymphocytes was observed. These findings were consistent with the notion that leukocytes play a role in atherosclerosis by the formation of foam cells.
- Effect of Glycosylated Plant Sterols on Fasting Plasma Triglycerides and Clolesterol Levels in two MBL-Deficient Patients and in one MBL-Normal Patient with Heterozygous Familial Hypercholesterolemia.
- Proof of the principle has been reached in 2 MBL-deficient patients.
- These subjects were treated with a diet enriched in glycosylated plant sterols during 3 weeks. The glycosylated plant sterols were selected in the MBL in vitro test as described in example 8. This intervention resulted in a decrease of fasting plasma triglycerides and cholesterol (Table 1)
TABLE 1 effect of glycosylated plant sterols on blood parameters of MBL-deficient patients. Plasma TG mM Cholesterol (mM) apoB (g/L) Before After Before After Before After MBL def1 3.66 2.27 4.8 4.2 0.85 0.89 MBL def2 0.88 0.79 4.8 3.6 0.62 0.56 - Using a different intervention with glycosylated plant stanols in a patient with heterozygous Familial Hypercholesterolemia (with relatively normal MBL activity in plasma), refractory to therapy with expanded doses of statins, in combination with a lipid lowering diet and resins, significant reductions of plasma cholesterol (from 10 to 7.8 mmol/L), fasting plasma triglycerides (from 2.3 to 1.08 mmol/L) and plasma apoB (from 1.90 to 1.62 g/L) were achieved reaching the lowest concentration ever experienced by this patient (FIG. 10). This example provides in vivo support for the Complement lipid pathway (CliP) concept developed by C-Tres, using a sub-optimal compounds.
- Effect of Vitamin A on Post Prandial CliP Stimulation.
- Another series of compounds, namely vitamin A-analoguesm, were tested in 20 healthy volunteers in order to determine the CLiP stimulating potency of the compounds that had shown CLiP stimulation in vitro (Example 8). Twenty healthy volunteers were tested on 2 different occasions. Blood was drawn before and after ingestion of a standardized oral fat load with and without vitamin A (as a representative for this series of compounds) given to the participants in random order. Addition of vitamin A to the oral fat load resulted in a significantly higher postprandial plasma C3 increase, whereas the same amount of fat was ingested in both situations (FIG. 11A).
- The levels of plasma trygliceride increase 2 h after acute oral fat load also showed a reduction in the volunteers, if the fat load was given with vitamin A (FIG. 11B)
- This is in line with the CLiP concept, by activating the Complement system, plasma triglycerides will be reduced even in healthy normolipidemic subjects. Note: It should be stressed that the C3 increase in this group of young, healthy, lean subjects was expected to be lower due to the characteristics of the subjects. In older, insulin-insensitive subjects the postprandial C3 response is much higher.
- These experiments in human gave the expected results upon administration: increase of C3-titers and decrease of triglycerides. Therefore, it is reasonable to assume that other compounds, active in the in vitro assay, will show CLiP-activities in human.
- Other Analytical Methods:
- Triglyceride-rich particles in plasma, chylomicrons and non-chylomicrons were determined by HPLC as described (14). TG and cholesterol were measured in duplicate by commercial calorimetric assay (GPO-PAP, and Monotest Cholesterol kit, Boehringer Mannheim) as described (14,23). Plasma apo B and apo AI were determined by immunoturbidimetry (23). Apo E genotype was determined as described (47-49). HDL2 and HDL3 cholesterol concentrations were determined by precipitation procedures as described (50). Complement
factor 3 was measured immunoturbidimetry or nephelometrically. Acylation stimulating protein was determined by ELISA, as were factor B and D. Ketone bodies were measured by HPLC. - References:
- All publications, patents, patent applications and other references cited herein are hereby incorporated by reference in their entirety for all purposes.
- 1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990's. Nature 1993; 362: 801-809.
- 2. Willeit J, Kiechl S, Oberhollenzer F, Rungger G, Egger G, Bonora E, Mitterer M, Muggeo M. Distinct risk profiles of early and advanced atheroclerosis. Prospective results from the Brunneck Study. Arterioscl Thromb Vasc Biol 2000; 20: 529-537.
- 3. Bucher H C, Griffith L E, Guyatt G H. Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscl Thromb Vasc Biol 1999; 19: 187-195.
- 4. The Heart Outcmes prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-53.
- 5. The Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
- 6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with
type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-53. - 7. Haffner S M, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with
type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34. - 8. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-126.
- 9. Law S K A & K B M Reid: Complement in focus, 2nd edition, 1995. Oxford University Press, Oxford, G.B.
- 10. Rosenberg M E & J Silkensen: Clusterin: Physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 1995; 27(7): 633-645.
- 11. Ishikawa Y, Akasaka Y, Ishii T, Komiyama K, Masuda S, Asuwa N, Choi-Miura N-H, Tomita M: Distribution and synthesis of apolipoprotein J in the atherosclerotic aorta. Artherioscler Thromb Vasc Biol 1998; 18:665-672.
- 12. Madsen H O, Videm V, Svejgaard A, Svennevig J L, Garred P: Association of mannose-binding-lectin deficiency with severe atherosclerosis. The Lancet 1998; 352:959-960.
Claims (44)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/327,631 US20030165458A1 (en) | 2000-09-12 | 2002-12-20 | Diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00203156.5 | 2000-09-12 | ||
EP00203156A EP1186299A1 (en) | 2000-09-12 | 2000-09-12 | The diagnosis, prevention, and/or succesful treatment of atherosclerosis, infectious diseases, and disturbances in the immune system |
US25346500P | 2000-11-28 | 2000-11-28 | |
PCT/NL2001/000672 WO2002022160A2 (en) | 2000-09-12 | 2001-09-12 | The diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism |
PCT/NL2001/000673 WO2002022161A2 (en) | 2000-09-12 | 2001-09-12 | The diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases |
US10/327,631 US20030165458A1 (en) | 2000-09-12 | 2002-12-20 | Diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL2001/000673 Continuation-In-Part WO2002022161A2 (en) | 2000-09-12 | 2001-09-12 | The diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases |
PCT/NL2001/000672 Continuation-In-Part WO2002022160A2 (en) | 2000-09-12 | 2001-09-12 | The diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030165458A1 true US20030165458A1 (en) | 2003-09-04 |
Family
ID=8172012
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/327,631 Abandoned US20030165458A1 (en) | 2000-09-12 | 2002-12-20 | Diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism |
US10/327,604 Expired - Fee Related US7498147B2 (en) | 2000-09-12 | 2002-12-20 | Diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases |
US12/215,297 Abandoned US20090162357A1 (en) | 2000-09-12 | 2008-06-25 | Diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/327,604 Expired - Fee Related US7498147B2 (en) | 2000-09-12 | 2002-12-20 | Diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases |
US12/215,297 Abandoned US20090162357A1 (en) | 2000-09-12 | 2008-06-25 | Diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases |
Country Status (6)
Country | Link |
---|---|
US (3) | US20030165458A1 (en) |
EP (3) | EP1186299A1 (en) |
JP (2) | JP2004508413A (en) |
AU (2) | AU2001294401A1 (en) |
CA (2) | CA2421994A1 (en) |
WO (2) | WO2002022161A2 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060045853A1 (en) * | 2002-07-09 | 2006-03-02 | Kroon-Batenburg Louise M J | Cross-beta structure comprising amyloid-binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity |
US20070003552A1 (en) * | 2002-07-09 | 2007-01-04 | Gebbink Martijn F B | Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation |
US20070015206A1 (en) * | 2005-07-13 | 2007-01-18 | Umc Utrecht Holding B.V. | Method for detecting and/or removing protien comprising a cross-beta structure from a pharmaceutical composition |
US20080118529A1 (en) * | 2005-07-13 | 2008-05-22 | Gebbink Martijn Frans Ben Gera | Adjuvation Through Cross -Beta Structure |
US20080249606A1 (en) * | 2005-07-13 | 2008-10-09 | Martijn Frans Ben Gerard Gebbink | Methods for Determining the Effect of a Treatment on the Cross-Beta Structure Content of a Protein; Selection of Treatments and Uses Thereof |
US20080267948A1 (en) * | 2005-07-13 | 2008-10-30 | Martijn Frans Ben Gerard Gebbink | Croos-B Structure Binding Compounds |
US20090142377A1 (en) * | 2007-11-08 | 2009-06-04 | Crossbeta Biosciences B.V. | Immunogenic compositions |
US20090202980A1 (en) * | 2005-03-21 | 2009-08-13 | Crossbeta Biosciences B.V. | Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation |
US20110008376A1 (en) * | 2007-11-08 | 2011-01-13 | Martijn Frans Ben Gerard Gebbink | Immunogenic compositions capable of activating t-cells |
US20140335546A1 (en) * | 2013-05-10 | 2014-11-13 | G J Carroll Pty Ltd | Devices and Methods for Determining the Risk of Developing a Serious Infection |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
US7199102B2 (en) | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
US7723303B2 (en) | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
EP1186299A1 (en) | 2000-09-12 | 2002-03-13 | Universitair Medisch Centrum Utrecht | The diagnosis, prevention, and/or succesful treatment of atherosclerosis, infectious diseases, and disturbances in the immune system |
US20030105003A1 (en) | 2001-04-05 | 2003-06-05 | Jan Nilsson | Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
SE0103754L (en) * | 2001-04-05 | 2002-10-06 | Forskarpatent I Syd Ab | Peptides from apolipoprotein B, use thereof immunization, method of diagnosis or therapeutic treatment of ischemic cardiovascular diseases, and pharmaceutical composition and vaccine containing such peptide |
CN1283313C (en) | 2001-09-28 | 2006-11-08 | 埃斯佩里安医疗公司 | Prevention and treatment of restenosis by local administration of drug |
US6930085B2 (en) | 2002-04-05 | 2005-08-16 | The Regents Of The University Of California | G-type peptides to ameliorate atherosclerosis |
US20080107639A1 (en) * | 2004-01-20 | 2008-05-08 | Develogen Aktiengesellschaft | Use of a Dg147 Protein Product for Preventing and Treating Metabolic Disorders |
JP2007531537A (en) | 2004-04-06 | 2007-11-08 | セダーズ−シナイ メディカル センター | Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein AI and apolipoprotein A-IMLANO |
WO2006031592A1 (en) * | 2004-09-09 | 2006-03-23 | University Of Massachusetts | Disease markers for early stage atherosclerosis |
CA2595067A1 (en) | 2004-12-06 | 2006-06-15 | The Regents Of The University Of California | Methods for improving the structure and function of arterioles |
US7972802B2 (en) | 2005-10-31 | 2011-07-05 | University Of Washington | Lipoprotein-associated markers for cardiovascular disease |
US8524453B2 (en) | 2006-02-10 | 2013-09-03 | The Brigham And Woman's Hospital, Inc. | Lectin complement pathway assays and related compositions and methods |
JP2010537638A (en) | 2007-08-28 | 2010-12-09 | ユーエービー リサーチ ファウンデーション | Synthetic apolipoprotein E mimetic polypeptides and methods of use |
JP2010538005A (en) | 2007-08-28 | 2010-12-09 | ユーエービー リサーチ ファウンデーション | Synthetic apolipoprotein E mimetic polypeptides and methods of use |
EP2257646A1 (en) * | 2008-02-29 | 2010-12-08 | ISIS Innovation Limited | Diagnostic methods |
US9817001B2 (en) | 2008-05-27 | 2017-11-14 | Boston Heart Diagnostics Corporation | Methods for determining LDL cholesterol treatment |
US8241861B1 (en) | 2008-07-08 | 2012-08-14 | Insilicos, Llc | Methods and compositions for diagnosis or prognosis of cardiovascular disease |
US8937046B2 (en) * | 2008-09-22 | 2015-01-20 | The Regents Of The University Of Colorado, A Body Corporate | Modulating the alternative complement pathway |
US8470541B1 (en) | 2008-09-27 | 2013-06-25 | Boston Heart Diagnostics Corporation | Methods for separation and immuno-detection of biomolecules, and apparatus related thereto |
JP5453667B2 (en) * | 2008-09-30 | 2014-03-26 | 株式会社バイオス医科学研究所 | Arteriosclerosis detection method and arteriosclerosis marker |
HU0900534D0 (en) * | 2009-08-29 | 2009-10-28 | Semmelweis Egyetem | Method and kit for improvement of prognosing of heart failure |
GB201003920D0 (en) * | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Method of treatment |
AU2011336997A1 (en) | 2010-11-12 | 2013-05-30 | Cedars-Sinai Medical Center | Immunomodulatory methods and systems for treatment and/or prevention of hypertension |
RU2013126628A (en) | 2010-11-12 | 2014-12-20 | Седарс-Синаи Медикал Сентер | IMMUNOMODULATING METHODS AND SYSTEMS FOR TREATING AND / OR PREVENTING ANEURISM |
WO2013033518A1 (en) * | 2011-09-02 | 2013-03-07 | The Medicines Company | Methods for treating properdin-related diseases or disorders |
CA2851838A1 (en) | 2011-10-13 | 2013-04-18 | Boston Heart Diagnostics Corporation | Compositions and methods for treating and preventing coronary heart disease |
EP2794656B1 (en) | 2011-12-21 | 2019-02-27 | Novartis AG | Compositions comprising antibodies targeting factor p and c5 |
US9828624B2 (en) | 2013-07-24 | 2017-11-28 | Boston Heart Diagnostics Corporation | Driving patient compliance with therapy |
JP7081923B2 (en) | 2014-07-31 | 2022-06-07 | ユーエイビー リサーチ ファンデーション | Higher effectiveness for removing apoE mimetic peptides and plasma cholesterol |
EP3220810A4 (en) | 2014-11-17 | 2018-05-16 | Boston Heart Diagnostic Corporation | Cardiovascular disease risk assessment |
WO2017210360A1 (en) * | 2016-05-31 | 2017-12-07 | Cardiovax, Llc | Methods for diagnosing and treating systemic lupus erythematosus |
US10858422B2 (en) | 2016-05-31 | 2020-12-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989001519A1 (en) * | 1987-08-20 | 1989-02-23 | Children's Hospital Corporation | Human mannose binding protein |
EP0649468B1 (en) | 1992-06-24 | 2000-03-15 | AdProTech plc | Soluble cr1 derivatives |
US6001828A (en) * | 1995-06-05 | 1999-12-14 | Andrulis, Jr.; Peter | Use of tumor factor inhibitors together with antiviral agents and therapeutic compositions thereof against HIV infection |
US6197596B1 (en) * | 1997-12-04 | 2001-03-06 | Mcgill University | Monitoring and/or prognostic of antibody-mediated autoimmune diseases |
JPH11349488A (en) * | 1998-06-01 | 1999-12-21 | Hisamitsu Pharmaceut Co Inc | Immunosuppresant containing clusterin |
US6464975B2 (en) * | 1998-12-11 | 2002-10-15 | The Research Foundation Of State University Of New York | Compositions and methods for altering cell migration |
JP2002532079A (en) * | 1998-12-15 | 2002-10-02 | ザ ブライハム アンド ウイミンズ ホスピタル, インコーポレイテッド | Methods and products for modulating the lectin complement pathway associated with complement activation |
PT1181363E (en) * | 1999-05-14 | 2007-05-31 | Steffen Thiel | Recombinant human mannan-binding lectin |
US7387993B2 (en) * | 2000-07-13 | 2008-06-17 | Natimmune A/S | Mannan-binding lectin (MBL) treatment of infections in individuals treated with TNF-αinhibitors |
EP1186299A1 (en) | 2000-09-12 | 2002-03-13 | Universitair Medisch Centrum Utrecht | The diagnosis, prevention, and/or succesful treatment of atherosclerosis, infectious diseases, and disturbances in the immune system |
-
2000
- 2000-09-12 EP EP00203156A patent/EP1186299A1/en not_active Withdrawn
-
2001
- 2001-09-12 EP EP01975033A patent/EP1318832A2/en not_active Ceased
- 2001-09-12 JP JP2002526410A patent/JP2004508413A/en active Pending
- 2001-09-12 WO PCT/NL2001/000673 patent/WO2002022161A2/en not_active Application Discontinuation
- 2001-09-12 JP JP2002526411A patent/JP2004508414A/en active Pending
- 2001-09-12 WO PCT/NL2001/000672 patent/WO2002022160A2/en not_active Application Discontinuation
- 2001-09-12 EP EP01975032A patent/EP1318831A2/en not_active Ceased
- 2001-09-12 CA CA002421994A patent/CA2421994A1/en not_active Abandoned
- 2001-09-12 CA CA002422032A patent/CA2422032A1/en not_active Abandoned
- 2001-09-12 AU AU2001294401A patent/AU2001294401A1/en not_active Abandoned
- 2001-09-12 AU AU2001294402A patent/AU2001294402A1/en not_active Abandoned
-
2002
- 2002-12-20 US US10/327,631 patent/US20030165458A1/en not_active Abandoned
- 2002-12-20 US US10/327,604 patent/US7498147B2/en not_active Expired - Fee Related
-
2008
- 2008-06-25 US US12/215,297 patent/US20090162357A1/en not_active Abandoned
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060045853A1 (en) * | 2002-07-09 | 2006-03-02 | Kroon-Batenburg Louise M J | Cross-beta structure comprising amyloid-binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity |
US20070003552A1 (en) * | 2002-07-09 | 2007-01-04 | Gebbink Martijn F B | Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation |
US8158585B2 (en) | 2002-07-09 | 2012-04-17 | Crossbeta Biosciences B.V. | Cross-β structure comprising amyloid-binding proteins and methods for detection of the cross-β structure, for modulating cross-β structures fiber formation and modulating cross-β structure-mediated toxicity |
US20090202980A1 (en) * | 2005-03-21 | 2009-08-13 | Crossbeta Biosciences B.V. | Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation |
US20080267948A1 (en) * | 2005-07-13 | 2008-10-30 | Martijn Frans Ben Gerard Gebbink | Croos-B Structure Binding Compounds |
US20080249606A1 (en) * | 2005-07-13 | 2008-10-09 | Martijn Frans Ben Gerard Gebbink | Methods for Determining the Effect of a Treatment on the Cross-Beta Structure Content of a Protein; Selection of Treatments and Uses Thereof |
US20080207488A1 (en) * | 2005-07-13 | 2008-08-28 | Gebbink Martijn Frans Ben Gera | Method for Detecting Peptides Comprising a Cross-B Structure |
US20080118529A1 (en) * | 2005-07-13 | 2008-05-22 | Gebbink Martijn Frans Ben Gera | Adjuvation Through Cross -Beta Structure |
US8067187B2 (en) | 2005-07-13 | 2011-11-29 | Crossbeta Biosciences B.V. | Cross-β structure binding compounds |
US8114832B2 (en) | 2005-07-13 | 2012-02-14 | Crossbeta Biosciences B.V. | Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition |
US20070015206A1 (en) * | 2005-07-13 | 2007-01-18 | Umc Utrecht Holding B.V. | Method for detecting and/or removing protien comprising a cross-beta structure from a pharmaceutical composition |
US20090142377A1 (en) * | 2007-11-08 | 2009-06-04 | Crossbeta Biosciences B.V. | Immunogenic compositions |
US20110008376A1 (en) * | 2007-11-08 | 2011-01-13 | Martijn Frans Ben Gerard Gebbink | Immunogenic compositions capable of activating t-cells |
US20110052564A1 (en) * | 2007-11-08 | 2011-03-03 | Martijn Frans Ben Gerard Gebbink | Enhancement of immunogenicity of antigens |
US20140335546A1 (en) * | 2013-05-10 | 2014-11-13 | G J Carroll Pty Ltd | Devices and Methods for Determining the Risk of Developing a Serious Infection |
Also Published As
Publication number | Publication date |
---|---|
WO2002022161A3 (en) | 2002-08-08 |
CA2421994A1 (en) | 2002-03-21 |
WO2002022160A3 (en) | 2002-08-15 |
JP2004508414A (en) | 2004-03-18 |
US20030143223A1 (en) | 2003-07-31 |
JP2004508413A (en) | 2004-03-18 |
US7498147B2 (en) | 2009-03-03 |
WO2002022161A2 (en) | 2002-03-21 |
WO2002022160A2 (en) | 2002-03-21 |
AU2001294402A1 (en) | 2002-03-26 |
CA2422032A1 (en) | 2002-03-21 |
AU2001294401A1 (en) | 2002-03-26 |
EP1318831A2 (en) | 2003-06-18 |
EP1186299A1 (en) | 2002-03-13 |
US20090162357A1 (en) | 2009-06-25 |
EP1318832A2 (en) | 2003-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7498147B2 (en) | Diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases | |
JP5300820B2 (en) | Peptide-based immunotherapy for the treatment of atherosclerosis and the development of peptide-based assays for measuring the immune response to oxidized low density lipoprotein | |
US8029786B2 (en) | Antibodies against a peptide epitope of apolipoprotein B | |
Choi-Miura et al. | Elevated complement activities of sera from patients with high density lipoprotein deficiency (Tangier disease): the presence of normal level of clusterin and the possible implication in the atherosclerosis | |
Aviram et al. | Postprandial plasma lipoproteins in normal and hypertriglyceridaemic subjects and their in vitro effect on platelet activity: differences between saturated and polyunsaturated fats | |
Patanapirunhakit | High density lipoprotein composition and function in healthy pregnancy and preeclampsia | |
Pemberger | Effects of chronic renal failure on macrophage cholesterol efflux | |
Camerotto | OBESITY AND METABOLIC SYNDROME: PLASMA LIPOPROTEINS ALTERATIONS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UNIVERSITEIT UTRECHT, NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CABEZAS, MANUEL CASTRO;VAN DIJK, HANS;REEL/FRAME:014031/0993;SIGNING DATES FROM 20030417 TO 20030422 Owner name: UNIVERSITAIR MEDISCH CENTRUM UTRECHT, NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CABEZAS, MANUEL CASTRO;VAN DIJK, HANS;REEL/FRAME:014031/0993;SIGNING DATES FROM 20030417 TO 20030422 |
|
AS | Assignment |
Owner name: CROSSBETA BIOSCIENCES B.V., NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:UNIVERSITAIR MEDISCH CENTRUM UTRECHT;UNIVERSITEIT UTRECHT;REEL/FRAME:018529/0097 Effective date: 20060918 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |